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A B S T R A C T
Background
Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in older people. Opioids
may be a viable treatment option if people have severe pain or if other analgesics are contraindicated. However, the evidence about
their effectiveness and safety is contradictory. This is an update of a Cochrane review first published in 2009.
Objectives
Todetermine the effects on pain, function, safety, and addiction of oral or transdermal opioids comparedwith placebo or no intervention
in people with knee or hip osteoarthritis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL (up to 28 July
2008, with an update performed on 15 August 2012), checked conference proceedings, reference lists, and contacted authors.
Selection criteria
We included randomised or quasi-randomised controlled trials that compared oral or transdermal opioids with placebo or no treatment
in people with knee or hip osteoarthritis. We excluded studies of tramadol. We applied no language restrictions.
Data collection and analysis
We extracted data in duplicate. We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain and
function, and risk ratios for safety outcomes. We combined trials using an inverse-variance random-effects meta-analysis.
Main results
We identified 12 additional trials and included 22 trials with 8275 participants in this update. Oral oxycodone was studied in 10
trials, transdermal buprenorphine and oral tapentadol in four, oral codeine in three, oral morphine and oral oxymorphone in two,
and transdermal fentanyl and oral hydromorphone in one trial each. All trials were described as double-blind, but the risk of bias for
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other domains was unclear in several trials due to incomplete reporting. Opioids were more beneficial in pain reduction than control
interventions (SMD -0.28, 95% CI -0.35 to -0.20), which corresponds to a difference in pain scores of 0.7 cm on a 10-cm visual
analogue scale (VAS) between opioids and placebo. This corresponds to a difference in improvement of 12% (95% CI 9% to 15%)
between opioids (41%mean improvement from baseline) and placebo (29%mean improvement from baseline), which translates into a
number needed to treat (NNTB) to cause one additional treatment response on pain of 10 (95% CI 8 to 14). Improvement of function
was larger in opioid-treated participants compared with control groups (SMD -0.26, 95% CI -0.35 to -0.17), which corresponds to a
difference in function scores of 0.6 units between opioids and placebo on a standardised Western Ontario and McMaster Universities
Arthritis Index (WOMAC) disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 11% (95% CI
7% to 14%) between opioids (32% mean improvement from baseline) and placebo (21% mean improvement from baseline), which
translates into an NNTB to cause one additional treatment response on function of 11 (95% CI 7 to 14). We did not find substantial
differences in effects according to type of opioid, analgesic potency, route of administration, daily dose, methodological quality of trials,
and type of funding. Trials with treatment durations of four weeks or less showed larger pain relief than trials with longer treatment
duration (P value for interaction = 0.001) and there was evidence for funnel plot asymmetry (P value = 0.054 for pain and P value
= 0.011 for function). Adverse events were more frequent in participants receiving opioids compared with control. The pooled risk
ratio was 1.49 (95% CI 1.35 to 1.63) for any adverse event (9 trials; 22% of participants in opioid and 15% of participants in control
treatment experienced side effects), 3.76 (95% CI 2.93 to 4.82) for drop-outs due to adverse events (19 trials; 6.4% of participants
in opioid and 1.7% of participants in control treatment dropped out due to adverse events), and 3.35 (95% CI 0.83 to 13.56) for
serious adverse events (2 trials; 1.3% of participants in opioid and 0.4% of participants in control treatment experienced serious adverse
events). Withdrawal symptoms occurred more often in opioid compared with control treatment (odds ratio (OR) 2.76, 95% CI 2.02
to 3.77; 3 trials; 2.4% of participants in opioid and 0.9% of participants control treatment experienced withdrawal symptoms).
Authors’ conclusions
The small mean benefit of non-tramadol opioids are contrasted by significant increases in the risk of adverse events. For the pain
outcome in particular, observed effects were of questionable clinical relevance since the 95% CI did not include the minimal clinically
important difference of 0.37 SMDs, which corresponds to 0.9 cm on a 10-cm VAS.
P L A I N L A N G U A G E S U M M A R Y
Opioids for osteoarthritis
This summary of a Cochrane review of 22 studies with 8275 participants (search update: 15 August 2012) presents what we know from
research about the effect of opioids on osteoarthritis (OA). We searched scientific databases for clinical trials looking at pain, function,
safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis.
The review shows that in people with osteoarthritis:
- Opioids have a small effect on pain or physical function.
- Opioids probably cause side effects. However, we do not have precise information about rare but serious side effects.
What is osteoarthritis and what are opioids?
OA is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try to repair the damage. Instead
of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen
and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
Opioids are generally conceived as powerful pain-relieving substances that are used for the pain of cancer or osteoarthritis. Some
examples of opioids are codeine-containing Tylenol® (1, 2, 3, and 4), hydromorphone (Dilaudid), oxycodone (Percocet, Percodan),
morphine, and others. They can be taken in a pill form, as an injection, or as a patch placed on the painful area.
Best estimate of what happens to people with osteoarthritis who take opioids
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Pain
- People who took opioids rated improvement in their pain to be about 3 points on a scale of 0 (no pain) to 10 (extreme pain) after
one month.
- People who took a placebo rated improvement in their pain to be about 2 points on a scale of 0 (no pain) to 10 (extreme pain) after
one month.
Another way of saying this is:
- 41 people out of 100 who used opioids responded to treatment (41%).
- 31 people out of 100 who used placebo responded to treatment (31%).
- 10 more people responded to treatment with opioids than with placebo (difference of 10%). (High-quality evidence)
Physical function
- People who took opioids rated improvement in their physical function to be about 2 points on a scale of 0 (no disability) to 10
(extreme disability) after one month.
- People who took a placebo rated improvement in their physical function to be about 1 point on a scale of 0 (no disability) to 10
(extreme disability) after one month.
Another way of saying this is:
- 34 people out of 100 who used opioids responded to treatment (34%).
- 26 people out of 100 who used placebo responded to treatment (26%).
- 8 more people responded to treatment with opioids than with placebo (difference of 8%). (High-quality evidence)
Side effects
- 22 people out of 100 who used opioids experienced side effects (22%).
- 15 people out of 100 who used a placebo experienced side effects (15%).
- 7 more people experienced side effects with opioids than with placebo (difference of 7%). (Moderate-quality evidence)
Drop-outs because of side effects
- 64 people out of 1000 who used opioids dropped out because of side effects (6.4%).
- 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).
- 47 more people dropped out because of side effects with opioids than with placebo (difference of 4.7%). (High-quality evidence)
Side effects resulting in hospitalisation, persistent disability, or death
- 13 people out of 1000 who used opioids experienced side effects resulting in hospitalisation, persistent disability, or death (1.3%).
- 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or deaths (0.4%).
- 9 more people experienced side effects resulting in hospitalisation, persistent disability, or death with opioids than with placebo
(difference of 0.9%). (Low-quality evidence)
Withdrawal symptoms
- 24 people out of 1000 who used opioids experienced withdrawal symptoms (2.4%).
- 9 people out of 1000 who used a placebo experienced withdrawal symptoms (0.9%).
- 15 more people experienced withdrawal symptoms with opioids than with placebo (difference of 1.5%). (Moderate-quality evidence)
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip
Patient or population: participants with osteoarthritis of the knee or hip
Settings: various orthopaedic or rheumatology clinics
Intervention: oral or transdermal opioids
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Opioids
Pain intensity
Various pain scales.
(median follow-up: 4
weeks)
-1.8 cm change
on 10-cm VAS1
29% improvement
-2.5 cm change
(1 -0.7 cm, -0.9 to -0.5)
2
41% improvement
(1 12%, 9% to 15%)3
SMD -0.28 (-0.35 to -0.
20)
8275
(22)
++++
high
NNTB 10 (95% CI 8 to 14)
4
Function
Various validated function
scales.
(median follow-up: 5
weeks)
-1.2 units
on WOMAC (range 0 to
10)1
21% improvement
-1.8 units on WOMAC
(1 -0.6, -0.8 to -0.4)5
32% improvement
(1 11%, 7% to 14%)6
SMD -0.26 (-0.35 to -0.
17)
3553
(12)
++++
high
NNTB 12 (95% CI 10 to
18)7
Number of participants
experiencing any ad-
verse event
(median follow-up: 8
weeks)
150 per 1000 participant-
years8
224 per 1000 participant-
years
(203 to 245)
RR 1.49 (1.35 to 1.63) 4898
(9)
+++O
moderate9
NNTH 14 (95% CI 11 to
19)
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Number of participants
who withdrew because
of adverse events
(median follow-up: 6
weeks)
17 per 1000 participant-
years8
64 per 1000 participant-
years
(50 to 82)
RR 3.76 (2.93 to 4.82) 7712
(19)
++++
high
NNTH 21 (95% CI 15 to
30)
Number of participants
experiencing any seri-
ous adverse event
(median follow-up: 8
weeks)
4 per 1000 participant-
years8
13 per 1000 participant-
years
(3 to 54)
RR 3.35 (0.83 to 13.56) 681
(3)
++OO
low10
Little evidence of harmful
effect (NNTH not statisti-
cally significant)
Withdrawal symptoms
(median follow-up: 16
weeks)
9 per 1000 participant-
years11
24 per 100
participant-years
(18 to 33)
OR 2.67 (2.02 to 3.77) 1151
(3)
+++O
moderate12
NNTH 65 (95% CI 42 to
110)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to
treat for an additional harmful outcome; OR: odds ratio; RR: risk ratio; SMD: standardised mean difference; WOMAC: Western Ontario and McMaster Universities Arthritis Index
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate.
1 Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
2 SMDs were back-transformed onto a 10-cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of
2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72
|SD units in the control group.
3 Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis
trials of 6.1 cm on 10-cm VAS (Nüesch 2009).
4 Absolute response risks for pain in the control groups were assumed 31% (see methods section).
5
O
ra
l
o
r
tra
n
sd
e
rm
a
l
o
p
io
id
s
fo
r
o
ste
o
a
rth
ritis
o
f
th
e
k
n
e
e
o
r
h
ip
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
5 SMDs were back-transformed onto a standardised WOMAC disability score ranging from 0 to 10 on the basis of a typical pooled SD
of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised
reduction of 0.58 standard deviation units in the control group.
6 Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of
large osteoarthritis trials of 5.6 units (Nüesch 2009).
7 Absolute response risks for function in the control groups were assumed 26% (see methods section).
8 Median control risk across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
9 Downgraded (1 level) because: 9 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias.
10 Downgraded (2 levels) because: 3 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias, the
CI of the pooled estimate is wide and crossed no difference.
11 Median risk across control groups in included trials.
12 Downgraded (1 level) because 3 out of 22 studies reported this outcome, possible leading to selective outcome reporting bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Osteoarthritis is the most common form of joint disease and the
leading cause of pain, functional limitations, and loss of indepen-
dence in older adults (Altman 1986). It is a progressive disease of
synovial joints resulting from biomechanical and systemic effects,
and is characterised by a breakdown of the joint cartilage accompa-
nied by subchondral bone changes, deterioration of tendons and
ligaments, and various degrees of inflammation of the synovium
(Hochberg 2012).
Description of the intervention
Pharmacological therapy for osteoarthritis, as an alternative or in
addition to other therapeutic options, consists mainly of analgesics
and non-steroidal anti-in ammatory drugs (NSAIDs). However,
paracetamol may be inadequate to treat more severe, long-term
pain in osteoarthritis and chronic NSAID use may cause serious
gastrointestinal and cardiovascular adverse events. Opioids could
be a viable alternative if people have severe pain with insufficient
response to conventional treatment or if other analgesics are con-
traindicated (Avouac 2007).
How the intervention might work
Opioids are potent analgesics that work by targeting mainly spinal
and supraspinal opioid receptors. In addition, cellular studies sug-
gest that there are peripheral opioid receptors in inflamed os-
teoarthritic synovial tissue, which may mediate analgesic effects
(Stein 1996).
Why it is important to do this review
The American College of Rheumatology guidelines on manage-
ment of osteoarthritis, updated in 2012, suggest that opioids can
be used in people with osteoarthritis after having failed medical
therapy who were not willing or had contraindications for total
joint replacement (Hochberg 2012). British guidelines propose
opioids as an alternative if inadequate pain relief is achieved with
topical NSAIDs or paracetamol (Eccles 1998; NICE 2008). How-
ever, the use of strong opioids for the treatment of non-cancer pain
remains controversial. Concerns have been expressed about long-
term use of opioids for chronic non-cancer pain mainly due to the
risks of addiction (Von Korff 2004; Zhang 2008).
O B J E C T I V E S
To determine the effects on pain, function, safety, and addiction
of oral or transdermal opioids compared with placebo or no inter-
vention in people with knee or hip osteoarthritis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving placebo or no intervention.
Types of participants
At least 75% of participants with clinically or radiologically con-
firmed osteoarthritis of the knee or hip. We did not consider trials
exclusively including people with inflammatory arthritis, such as
rheumatoid arthritis.
Types of interventions
Any type of opioid except tramadol, which is covered in a separate
Cochrane Review (Cepeda 2006).
Types of outcome measures
Primary outcomes
The main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham 2004). If
data on more than one pain scale were provided for a trial, we
referred to a previously described hierarchy of pain-related out-
comes (Jüni 2006; Reichenbach 2007), and extracted data on the
pain scale that was highest on this list:
1. global pain;
2. pain on walking;
3. Western Ontario and McMaster Universities Arthritis Index
(WOMAC) osteoarthritis index pain subscore;
4. composite pain scores other than WOMAC;
5. pain on activities other than walking;
6. rest pain or pain during the night;
7. WOMAC global algofunctional score;
8. Lequesne osteoarthritis index global score;
9. other algofunctional scale;
10. participant’s global assessment;
11. physician’s global assessment.
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy:
7Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. global disability score;
2. walking disability;
3. WOMAC disability subscore;
4. composite disability scores other than WOMAC;
5. disability other than walking;
6. WOMAC global scale;
7. Lequesne osteoarthritis index global score;
8. other algofunctional scale;
9. participant’s global assessment;
10. physician’s global assessment.
If pain or function outcomes were reported at several time points,
we extracted the measure at the end of the treatment period.
Secondary outcomes
Secondary outcomes were the number of participants who experi-
enced any adverse event, withdrew because of adverse events, expe-
rienced any serious adverse events, and experienced symptoms of
opioid dependence such as craving or physical withdrawal symp-
toms. We defined serious adverse events as events resulting in hos-
pitalisation, prolongation of hospitalisation, persistent or signifi-
cant disability, congenital abnormality or birth defect of offspring,
life-threatening events, or death.
Search methods for identification of studies
Electronic searches
We
searched the electronic databases the Cochrane Central Register
of Controlled Trials (CENTRAL) (mrw.interscience.wiley.com/
cochrane/),MEDLINE and EMBASE through theOvid platform
(www.ovid.com), and CINAHL through EBSCOhost (all from
implementation to July 28 2008) using truncated variations of
preparation names including brand names combined with trun-
cated variations of terms related to osteoarthritis, all as text words.
We applied a validated methodological filter for controlled clini-
cal trials (Dickersin 1994). The specific search algorithms are dis-
played in Appendix 1 and Appendix 2. We updated the search
using CENTRAL, MEDLINE, and EMBASE up to 15 August
2012.
Searching other resources
We manually searched conference proceedings, used Science Ci-
tation Index to retrieve reports citing relevant articles, con-
tacted content experts and trialists, and screened reference
lists of all obtained articles. Finally, we searched several clini-
cal trial registries (clinicaltrials.gov, metaRegister of Controlled
Trials, Australian New Zealand Clinical Trials Registry, UMIN
Clinical Trials Registry) to identify ongoing trials. We performed
the last update of the search on 20 September 2012. We did not
search OARSI conference proceedings for the update, as we no
longer had access to this database.
Data collection and analysis
We used a generic protocol with instructions for data extraction,
quality assessment, and statistical analyses, which was approved by
the editorial board of the Cochrane Musculoskeletal Group. We
applied the same protocol in our previous reviews (Rutjes 2009a;
Rutjes 2009b; Reichenbach 2010; Rutjes 2010; da Costa 2012b).
Selection of studies
Two review authors independently evaluated all titles and abstracts
for eligibility (originally EN and AR, BdC and RK for the up-
date) (see Figure 1). We resolved disagreements by discussion. We
applied no language restrictions. If multiple reports described the
same trial, we considered all.
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Figure 1. Study flow chart.
Data extraction and management
Two review authors (originally EN and AR, BdC and RK for the
update) extracted trial information independently using a stan-
dardised, piloted extraction form accompanied by a codebook.
We resolved disagreements by discussion. We extracted both the
generic and trade name of the experimental intervention, the type
of control used, dosage, frequency, route of administration, dura-
tion of treatment, participant characteristics (gender,mean age and
duration of symptoms, types of joints affected), types of measures
used and pain- and function-related outcomes, trial design, trial
size, duration of follow-up, type and source of financial support,
and publication status. When necessary, we approximated means
and measures of dispersion from figures in the reports. For cross-
over trials, we extracted data from the first period only. When-
ever possible, we used results from an intention-to-treat analysis.
If effect sizes could not be calculated, we contacted the authors for
additional data.
Assessment of risk of bias in included studies
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Two review authors (originally EN and AR, BdC and RK for the
update) independently assessed randomisation, blinding, and ade-
quacy of analyses (Jüni 2001). We resolved disagreements by con-
sensus. We assessed two components of randomisation: genera-
tion of allocation sequences and concealment of allocation. We
considered generation of sequences to be adequate if it resulted in
an unpredictable allocation schedule; mechanisms considered ad-
equate included random-number tables, computer-generated ran-
dom numbers, minimisation, coin tossing, shuffling cards, and
drawing lots. We considered trials using an unpredictable alloca-
tion sequence to be randomised; we considered trials using poten-
tially predictable allocationmechanisms, such as alternation or the
allocation of participants according to date of birth, to be quasi-
randomised. We considered concealment of allocation to be ade-
quate if participants and investigators responsible for participant
selection were unable to suspect before allocation which treatment
was next. Methods considered adequate include central randomi-
sation; pharmacy-controlled randomisation using identical pre-
numbered containers; and sequentially numbered, sealed, opaque
envelopes. We considered blinding of participants to be adequate
if experimental and control preparations were explicitly described
as indistinguishable or if a double-dummy technique was used.
We considered analyses to be adequate if all randomised partic-
ipants were included in the analysis according to the intention-
to-treat principle. We further assessed the reporting of primary
outcomes, sample size calculations, and funding source. Finally,
we used GRADE to describe the quality of the overall body of
evidence (Guyatt 2008; Higgins 2011), defined as the extent of
confidence into the estimates of treatment benefits and harms.
Measures of treatment effect
We summarised continuous outcomes using standardised mean
differences (SMD) with 95% confidence intervals (CI), with the
differences in mean values at the end of treatment across treatment
groups divided by the pooled standard deviation (SD). If differ-
ences in mean values at the end of the treatment were unavail-
able, we used differences in mean changes. If some of the required
data were unavailable, we used approximations, as previously de-
scribed (Reichenbach 2007). An SMD of -0.20 SD units can be
considered a small difference between the experimental and con-
trol groups, an SMD of -0.50 a moderate difference, and -0.80
a large difference (Cohen 1988; Jüni 2006). SMDs can also be
interpreted in terms of the per cent of overlap of the experimental
group’s scores with scores of the control group. An SMD of -0.20
indicates an overlap in the distribution of pain or function scores
in about 85% of cases, an SMD of -0.50 in about 67%, and an
SMD of -0.80 in about 53% of cases (Cohen 1988; Jüni 2006).
On the basis of a median pooled SD of 2.5 cm, found in large-
scale osteoarthritis trials that assessed pain using a 10-cm visual
analogue scale (VAS) (Nüesch 2009), SMDs of -0.20 correspond
to approximate differences in pain scores between experimental
and control groups of 0.5 on a 10-cm VAS, -0.50 of 1.25 on a 10-
cm VAS, and -0.80 of 2 on a 10-cm VAS. We back transformed
SMDs for function to a standardised WOMAC disability score
(Bellamy 1995), ranging from 0 to 10 on the basis of a median
pooled SD of 2.1 units observed in large-scale osteoarthritis trials
(Nüesch 2009). We expressed binary outcomes as risk ratios (RR)
with 95% CI.
Data synthesis
We used a standard inverse-variance random-effects meta-analysis
to combine the trials (DerSimonian 1986). We quantified hetero-
geneity between trials using the I2 statistic (Higgins 2003), which
describes the percentage of variation across trials that is attributable
to heterogeneity rather than to chance. I2 values of 25% may be
interpreted as low, 50% as moderate, and 75% as high between-
trial heterogeneity, although its interpretation depends on the size
and number of trials included (Rücker 2008). The association be-
tween trial size and treatment effects was investigated in funnel
plots, plotting effect sizes on the vertical axis against their standard
errors on the horizontal axis (Sterne 2011). We assessed asymme-
try by the asymmetry coefficient, the difference in effect size per
unit increase in standard error (Sterne 2001), which is mainly a
surrogate for sample size, and used univariable, meta-regression
analysis to predict treatment effects in trials as large as the largest
trials included in the meta-analysis using the standard error as the
explanatory variable (Shang 2005).We then performed analyses of
the primary outcomes, pain and function, stratified by the follow-
ing trial characteristics: type of opioid, analgesic potency (strong
versus weak), route of administration (oral versus transdermal),
type of control (placebo versus no intervention), concealment of
allocation (adequate versus inadequate or unclear), blinding of
participants (adequate versus inadequate or unclear), analysis in
accordance with the intention-to-treat principle (yes versus no or
unclear), trial size, funding (funding by pharmaceutical industry
or unclear versus no funding by pharmaceutical industry), dura-
tion of treatment, and type of osteoarthritis (hip only versus knee
only versus mixed). We classified buprenorphine, fentanyl, mor-
phine, oxycodone, oxymorphone, and tapentadol as strong opi-
oids, and codeine and dextropropoxyphene as weak opioids. We
used a cut-off of 200 allocated participants to distinguish between
small-scale and large-scale trials. A sample size of 2 x 100 par-
ticipants will yield more than 80% power to detect a small-to-
moderate SMD of -0.40 at a two-sided P value of 0.05, which
corresponds to a difference of 1 cm on a 10-cm VAS between the
experimental and control intervention (Nüesch 2010). We used a
cut-off of one month to distinguish between short-term and long-
term trials. We used univariable, random-effects meta-regression
models to determine whether treatment effects were affected by
these factors (Thompson 1999). In addition, we included the fol-
lowing two continuous variables at trial level in univariable meta-
regression: daily morphine equivalence dosage and treatment du-
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ration. We calculated morphine equivalence doses as previously
described: oral morphine 10 mg was considered equivalent to oral
codeine 65 mg, oral hydromorphone 2 mg, oral oxycodone 7.5
mg, and oral oxymorphone 10 mg and oral tapentadol 25 mg
(Loeser 2001; Schug 2006). Patches of fentanyl 25 µg/hour was
considered equivalent to oral morphine 90mg per day and patches
of buprenorphine 5, 10, and 20 µg/hour equivalent to 10, 15,
and 30 mg oral morphine per day (British Pain Society 2010).
We converted SMDs of pain intensity and function to odds ratios
(OR) (Chinn 2000; da Costa 2012a) to derive numbers needed to
treat to cause one additional treatment response on pain or func-
tion as compared with placebo (NNTB), and numbers needed to
treat to cause one additional adverse outcome (NNTH). We de-
fined treatment response as a 50% improvement in scores (Clegg
2006). With a median standardised pain intensity at baseline of
2.4 SDunits, observed in large osteoarthritis trials (Nüesch 2009),
this corresponds to a mean decrease in scores of 1.2 SD units.
Based on the median standardised decrease in pain scores of 0.72
SD units (Nüesch 2009), we calculated that a median of 31%
of participants in the placebo group would achieve an improve-
ment of pain scores of 50% or more. This percentage was used as
the control group response rate to calculate NNTBs for treatment
response on pain. Based on the median standardised WOMAC
function score at baseline of 2.7 SD units and the median stan-
dardised decrease in function scores of 0.58 SD units (Nüesch
2009), 26% of participants in the placebo group would achieve
a reduction in function of 50% or more. Again, this percentage
was used as the control group response rate to calculate NNTBs
for treatment response on function. We used the median risks of
150 participants with adverse events per 1000 participant-years,
four participants with serious adverse events per 1000 participant-
years, and 17 drop-outs due to adverse events per 1000 partic-
ipant-years as observed in placebo groups in large osteoarthritis
trials (Nüesch 2009), to calculate NNTHs for safety outcomes.
All P values were two-sided. We performed analyses using Review
Manager 5 (RevMan 2012), and STATA version 11.2 (StataCorp,
College Station, Texas).
R E S U L T S
Description of studies
We identified 5099 potentially relevant references through our
electronic searches (Figure 1); we excluded 4984 references after
screening titles and abstracts and retrieved 115 potentially relevant
references for full-text assessment. We included 22 randomised
controlled trials in the review. Checking reference lists, trial reg-
isters, and handsearching of conference proceedings yielded five
additional trials.
Three trials evaluated weak opioids. All three compared codeine
with placebo (Kjaersgaard-Andersen 1990; Quiding 1992; Peloso
2000), one of these with paracetamol 3000 mg daily as anal-
gesic co-intervention administered in both the experimental and
control groups (Kjaersgaard-Andersen 1990), and another with
ibuprofen 1200 mg daily administered in both groups (Quiding
1992). Strong opioids were compared with placebo in 19 tri-
als. Hydromorphone was used in one trial (NCT00980798),
morphine in two trials (Caldwell 2002; Katz 2010), oxymor-
phone in two trials (Matsumoto 2005; Kivitz 2006), oxycodone
in 10 trials (Chindalore 2005; Markenson 2005; Matsumoto
2005; Zautra 2005; Hartrick 2009; Afilalo 2010; Etropolski
2011; Fidelholtz 2011; Friedmann 2011; NCT00486811), and
tapentadol in four trials (Hartrick 2009; Afilalo 2010; Etropolski
2011; NCT00486811). Transdermal opioids were studied in
five trials: buprenorphine in four trials (Shannon 2005; Breivik
2010; Munera 2010; NCT00531427), and fentanyl in one trial
(Langford 2006). Opioids were administered at a median daily
dose of 59-mg morphine equivalents (range 13 to 160 mg).
The median treatment duration was four weeks (range three days
to six months). Trials randomised a median of 344 participants
(range 27 to 10301 participants). Twenty trials (90%) were multi-
centre trials, 21 were parallel group, and one was a cross-over trial
(Quiding 1992). Two trials exclusively included participants with
hip osteoarthritis (Kjaersgaard-Andersen 1990; Quiding 1992),
four trials included only participants with knee osteoarthritis
(Zautra 2005; NCT0048681; Afilalo 20101; NCT00531427),
and 16 trials included a mixed population of both knee and hip
osteoarthritis (Peloso 2000; Caldwell 2002; Chindalore 2005;
Markenson 2005;Matsumoto 2005; Shannon 2005; Kivitz 2006;
Langford 2006; Hartrick 2009; Breivik 2010; Katz 2010; Munera
2010; Etropolski 2011; Fidelholtz 2011; Friedmann 2011;
NCT00980798). In 17 studies, only participants with insuffi-
cient analgesic response to paracetamol, NSAIDs, or previous opi-
oid treatment were included (NCT00980798; NCT00531427;
Caldwell 2002; Chindalore 2005; Markenson 2005; Matsumoto
2005; Shannon 2005;Kivitz 2006; Langford 2006;Hartrick 2009;
Afilalo 2010; Breivik 2010; Katz 2010; Munera 2010; Etropolski
2011; Friedmann 2011;NCT00486811).None of these trials pro-
vided detailed information about the dosage of the analgesic treat-
ments before entering the trial. The three trials assessing codeine
included participants with a need for analgesic treatment but with-
out any requirement of previous insufficient treatment response
(Kjaersgaard-Andersen 1990; Quiding 1992; Peloso 2000); two
trials did not provide information about eligibility criteria con-
cerning the previous analgesic therapy (Zautra 2005; Fidelholtz
2011).
The Characteristics of excluded studies table displays the reasons
why we did not consider trials in this systematic review. Typi-
cal reasons were more than 25% of participants with rheumatoid
arthritis in the sample, the use of active control interventions, or
the use of cross-over designs without providing sufficient infor-
mation on the first phase.
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Risk of bias in included studies
Figure 2 summarises the methodological characteristics and
sources of funding of included trials. Six trials (27%) reported
both adequate sequence generation and adequate allocation con-
cealment (Markenson 2005; Kivitz 2006; Langford 2006; Afilalo
2010; Breivik 2010; Etropolski 2011), two trials reported only
adequate sequence generation (Matsumoto 2005; Hartrick 2009),
and two trials reported adequate concealment but remained un-
clear about the generation of allocation sequence (Zautra 2005;
Katz 2010). In the remaining 12 trials, low quality of report-
ing hampered any judgement regarding sequence generation and
concealment of allocation. All 22 trials were described as dou-
ble blind. Eleven trials reported the use of indistinguishable in-
terventions to blind participants whereas another four trials used
double-dummy techniques (Quiding 1992; Caldwell 2002; Kivitz
2006; Afilalo 2010). Fourteen trials explicitly reported adequate
blinding of physicians. Seventeen trials described their analysis
to be according to the intention-to-treat principle, but only one
trial was considered to have an intention-to-treat analysis of pain
(NCT00531427), and one trial of function outcomes at end of
treatment (Katz 2010), according to our criteria. Exclusion of par-
ticipants from the analysis of pain outcomes ranged from 0.6%
to 52% in the experimental groups and from 0% to 33% in the
control groups. For eight trials, no information was available on
the proportionof excludedparticipants (NCT00980798;Quiding
1992; Caldwell 2002; Markenson 2005; Langford 2006; Hartrick
2009; Fidelholtz 2011; NCT00486811). For the analysis of func-
tion outcomes, exclusion of participants ranged from 1% to 73%
in the experimental groups and from 0.6% to 53% in the control
groups; in four trials, no information was available on the pro-
portion of excluded patients (Caldwell 2002; Markenson 2005;
Langford 2006; NCT00486811).
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Figure 2. Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (-) a
high risk of bias on a specific item.
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All trials (95%) except for one (Quiding 1992) reported a primary
outcome of which eight explicitly reported it to be pre-specified
in the protocol (Peloso 2000; Caldwell 2002; Markenson 2005;
Matsumoto 2005; Langford 2006; Katz 2010; NCT00486811;
NCT00531427), and 13 trials reported a sample size calculation
for this primary outcome. Twenty trials received financial support
from a commercial organisation, two were unclear about their
source of funding (Kjaersgaard-Andersen 1990; Quiding 1992),
whereas no trial was explicitly supported by a non-profit organisa-
tion. For the effectiveness outcomes pain and function, the quality
of the evidence (Guyatt 2008) was classified as high in view of the
low risk of bias in the included trials and the low heterogeneity
between trials (Summary of findings for the main comparison).
For adverse event and serious adverse event outcomes, the quality
of the evidence (Guyatt 2008) was classified as moderate to low
because of the small number of trials reporting the outcomes and
the small number of serious adverse events, which resulted in im-
precise estimates (Summary of findings for the main comparison).
Effects of interventions
See: Summary of findings for the main comparison Oral or
transdermal opioids compared with placebo for osteoarthritis of
the knee or hip
Primary outcomes
Knee or hip pain
Twenty-two trials including 5180 participants in experimental
groups and 3095 participants in control groups contributed to the
analyses of knee or hip pain. Figure 3 presents results of the analy-
sis, overall and stratified according to type of opioid. In the overall
analysis, combined oral and transdermal opioids were more ef-
fective in pain reduction than control interventions (SMD -0.28,
95% CI -0.35 to -0.20), which corresponds to a difference in pain
scores of 0.7 cm on a 10-cm VAS between opioids and placebo.
This corresponds to a difference in improvement of 12% (95%CI
9% to 15%) between opioids and placebo (Summary of findings
for themain comparison), which translates into anNNTB to cause
one additional treatment response on pain of 10 (95% CI 8 to 14)
(Summary of findings for the main comparison). An I2 statistic of
58% indicated a moderate degree of between-trial heterogeneity
(P for heterogeneity < 0.001). A visual inspection of the funnel
plot suggested asymmetry (asymmetry coefficient -1.86, 95%CI -
3.50 to -0.21) and the test for asymmetry indicated some evidence
for asymmetry (P value = 0.054) (Figure 4). Benefits were mod-
erate for codeine (SMD -0.51, 95% CI -1.01 to -0.01; 3 trials);
small to moderate for oxycodone (SMD -0.31, 95% CI -0.47 to
-0.15; 10 trials), oxymorphone (SMD -0.39, 95% CI -0.58 to -
0.21; 2 trials), and tapentadol (SMD -0.31, 95% CI -0.46 to -
0.16, 4 trials); and small for morphine (SMD -0.25, 95%CI -0.42
to -0.09; 2 trials) and transdermal opioids such as buprenorphine
(SMD -0.19, 95% CI -0.30 to -0.09, 4 trials) and fentanyl (SMD
-0.22, 95%CI -0.42 to -0.03; 1 trial). No benefit was observed for
hydromorphone (SMD 0.04, 95% CI -0.19 to 0.28, 1 trial). The
CIs were wide and a test for interaction between benefit and type
of opioid was non-significant (P value = 0.66). Table 1 presents the
results of stratified analyses. We found little evidence for an asso-
ciation of SMDs with analgesic potency, route of administration,
type of control intervention, use of analgesic co-interventions, type
of osteoarthritis, concealment of allocation, adequate blinding of
participants, or intention-to-treat analysis. Effects were similar in
studies including participants with only knee osteoarthritis (SMD
-0.22, 95%CI -0.41 to -0.04, 4 trials), with only hip osteoarthritis
(SMD -0.33, 95% CI -0.93 to 0.28, 2 trials), and with knee or
hip osteoarthritis (SMD -0.29, 95% CI -0.38 to -0.20, 16 trials,
P value for interaction = 0.77). We found larger benefits in trials
with 200 or fewer randomised participants (difference in SMD -
0.23, 95% CI -0.49 to 0.02, P for interaction = 0.08) and in trials
with a short treatment duration of one month or less (difference
in SMD -0.25, 95% CI -0.37 to -0.13, P value for interaction
= 0.001). The effect of treatment duration on treatment benefits
was similar, when we restricted the analyses to large trials only (P
value for interaction 0.001). Thirty-three comparisons from 22
trials contributed to the analysis of a linear association between
equivalence dose and treatment benefit (Figure 5). We found little
evidence for a linear association between daily equivalence doses
and pain reduction (P value = 0.49).
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Figure 3. Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no
intervention) on knee or hip pain. Values on x-axis denote standardised mean differences. The plot is stratified
according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811
contributed with two comparisons and the standard error was inflated and the number of participants in the
placebo group was halved to avoid duplicate counting of participants when including both comparisons in the
overall meta-analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002,
Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled.
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Figure 4. Funnel plot for effects on knee or hip pain.Numbers on x axis refer to standardised mean
differences (SMDs), on y axis to standard errors of SMDs.
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Figure 5. Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of
morphine equivalents (x axis). The size of the circles is proportional to the random-effects weights that were
used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from
univariable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed
lines represent the 95% confidence intervals.
Function
Twelve studies including 2124 participants in experimental groups
and 1429 participants in control groups contributed to the analysis
of function. Improvement of function was larger in opioid-treated
participants compared with control groups (SMD -0.26, 95% CI
-0.35 to -0.17) (Figure 6), which corresponds to a difference in
function scores of 0.6 units between opioids and placebo on a
standardised WOMAC disability scale ranging from 0 to 10. This
corresponds to a difference in improvement of 11% (95% CI 7%
to 14%) between opioids and placebo (Summary of findings for
the main comparison), which translates into an NNTB to cause
one additional treatment response on function of 11 (95%CI 7 to
14) (Summary of findings for the main comparison). An I2 statis-
tic of 32% indicated a low degree of between-trial heterogeneity
(P value for heterogeneity = 0.12). We found a moderate benefit
for codeine (SMD -0.42, 95% CI -0.74 to -0.10; 2 trials) and
oxymorphone (SMD -0.38, 95% CI -0.56 to -0.19, 2 trials) and
small benefits for morphine (SMD -0.20, 95% CI -0.38 to -0.02,
2 trials), oxycodone (SMD -0.30, 95% CI -0.58 to -0.01, 4 trials),
tapentadol (SMD -0.15, 95% CI -0.45 to 0.16, 2 trials), and for
transdermal opioids such as buprenorphine (SMD -0.23, 95% CI
-0.40 to -0.05, 2 trials) and fentanyl (SMD -0.28, 95% CI -0.48
to -0.09; 1 trial). As was the case for pain, CIs of estimates were
wide and a test for interaction between benefit and type of opi-
oid was non-significant (P value = 0.87). Heterogeneity between
trials was low with an I2 statistic estimate of 32% (P value for
heterogeneity = 0.12). The funnel plot (Figure 7) appeared asym-
metrical (asymmetry coefficient -3.33, 95% CI -5.76 to -0.89, P
value for asymmetry = 0.011). Table 2 presents the results of the
stratified analyses. We found little evidence for an association of
SMDs with analgesic potency, route of administration, type of
control intervention, treatment duration, use of analgesic co-in-
terventions, type of osteoarthritis, allocation concealment, and in-
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tention-to-treat analysis. Effects were similar in studies including
participants with only knee osteoarthritis (SMD -0.16, 95% CI -
0.43 to 0.11, 2 trials), only hip OA (SMD -0.29, 95% CI -0.68 to
0.11, 1 trial), and knee or hip OA (SMD -0.31, 95% CI -0.41 to
-0.20, 9 trials, P value for interaction 0.45). Adequately powered
trials with 200 or more randomised participants tended to show
smaller improvements of function (difference in SMD 0.23, 95%
CI -0.06 to 0.52, P value for interaction = 0.11) and trials with ad-
equate participant blinding larger benefits of function (difference
in SMD -0.25, 95% CI -0.41 to -0.09, P value for interaction =
0.008). Eighteen comparisons from 12 trials contributed to the
analysis of a linear association between equivalence dose and treat-
ment benefit for function (Figure 8). We found no evidence for
an association between daily equivalence doses and improvement
of function (P value = 0.48).
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Figure 6. Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no
intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified
according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was
inflated and the number of participants in the placebo group was halved to avoid duplicate counting of
participants when including both comparisons in the overall meta-analysis. Data relating to the 3, 3, and 2
active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled.
19Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Funnel plot for effects on functioning of the knee or hip.Numbers on x axis refer to standardised
mean differences (SMDs), on y axis to standard errors of SMDs
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Figure 8. Standardised mean differences of function (y axis) are plotted against total daily dose of morphine
equivalents (x axis). The size of the circles is proportional to the random-effects weights that were used in the
meta-regression. The dotted line indicates predicted treatment effects (regression line) from univariable
meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines
represent the 95% confidence intervals.
Secondary outcomes
Ten trials reported the occurrence of any adverse event in 2490
out of 3222 participants in experimental groups and 891 of 1676
participants in control groups (Figure 9). Participants were 49%
more likely to experience adverse events in experimental groups
compared with placebo (RR 1.49, 95% CI 1.35 to 1.63). The
NNTH to cause one additional participant to experience an ad-
verse event, as compared to placebo, was 14 (95% CI 11 to 19)
(Summary of findings for the main comparison). We found high
heterogeneity between different studies (I2 = 71%, P value for het-
erogeneity < 0.001), but no evidence that RRs differed between
different types of opioids (P value for interaction = 0.47) or length
of treatment duration (P value = 0.09). Eighteen comparisons in
nine trials contributed to the analysis of the association between
equivalence dose and log relative risk (Figure 10). We found little
evidence for a relationship (P value = 0.24).
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Figure 9. Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid
and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according
to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811
contributed with two comparisons and the number of participants in the placebo group was halved to avoid
duplicate counting of participants when including both comparisons in the overall meta-analysis.
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Figure 10. Risk ratios of participants experiencing any adverse event between opioids and control groups (y
axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional
to the random-effects weights that were used in the meta-regression. The dotted line indicates predicted
treatment effects (regression line) from univariable meta-regression by using daily morphine equivalence
doses the explanatory variable, and dashed lines represent the 95% confidence intervals.
Twenty-one trials with 8128 participants contributed to the meta-
analysis of participants withdrawn or dropped out because of ad-
verse events (Figure 11). Participants receiving opioid therapywere
3.8 times as likely as participants receiving placebo to be with-
drawn or drop-out due to adverse events (RR 3.76, 95% CI 2.93
to 4.82), with moderate between-trial heterogeneity (I2 = 59%,
P value for heterogeneity < 0.001). The NNTH to cause one ad-
ditional drop-out or withdrawal due to adverse events compared
with placebo was 21 (95% CI 15 to 30) (Summary of findings
for the main comparison). We found the highest pooled RR for
oxycodone versus placebo (RR 5.55, 95% CI 3.47 to 8.87, 9 tri-
als) and the lowest pooled RR for morphine versus placebo (RR
2.12, 95% CI 0.87 to 5.15, 2 trials) but CIs were wide and a test
for interaction between type of opioids and relative risk of being
withdrawn or dropping out because of adverse events negative gave
a P value for interaction of 0.41. We found no evidence for an
association between treatment duration and risk of withdrawals
or drop-outs due to adverse events (P value for interaction 0.78).
Thirty-two comparisons in 22 trials contributed to the analysis
of the association between equivalence dose and log relative risk
(Figure 12). We found little evidence for a relationship (P value =
0.94).
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Figure 11. Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse
events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The
plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011,
and NCT00486811 contributed with two comparisons and the number of participants in the placebo group
was halved to avoid duplicate counting of participants when including both comparisons in the overall meta-
analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop-outs because of
adverse events occurred in either group.
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Figure 12. Risk ratios of participants withdrawn or dropped out because of adverse events between opioids
and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the
circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line
indicates predicted treatment effects (regression line) from univariable meta-regression by using daily
morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals.
Three trials with 681 participants contributed to the analysis of
participants experiencing any serious adverse event (Figure 13).
One trial reported one death in the oxycodone group, but no other
serious adverse events and was not included in the analysis (Afilalo
2010). Of the three trials included, one trial reported that no par-
ticipant experienced a serious adverse event (Kjaersgaard-Andersen
1990). Overall data from the remaining two trials indicated that
participants receiving opioids tended be more likely to experience
a serious adverse event (RR 3.35, 95% CI 0.83 to 13.56). Due to
the low number of trials and events, we neither performed an anal-
ysis of the association between treatment duration or equivalence
dose and log relative risk for this outcome, nor a calculation of
NNTH to cause one additional participant to experience a serious
adverse event compared with placebo.
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Figure 13. Forest plot of three trials comparing participants experiencing any serious adverse event
between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is
stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious
adverse event occurred in either group.
Three trials reported symptoms of opioid dependency (Langford
2006; Afilalo 2010; Katz 2010). Two studies reported 25 of 397
participants with withdrawal symptoms in oral opioids and five
of 255 in control groups (Afilalo 2010; Katz 2010). One study
assessed opiate withdrawal symptoms after eight weeks of trans-
dermal fentanyl therapy, using the Short OpiateWithdrawal Scale
questionnaire (Gossop 1990; Langford 2006). On average, partic-
ipants in the opioids groups had a 2.8-fold increased risk of with-
drawal symptoms compared with control groups with a pooled
OR of 2.76 (95% CI 2.02 to 3.77) (Figure 14). The NNTH to
cause one additional participant to experience withdrawal symp-
toms, as compared with control, was 65 (95% CI 42 to 110).
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Figure 14. Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal
symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios.
The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the
number of participants in the placebo group was halved to avoid duplicate counting of participants when
including both comparisons in the overall meta-analysis.
D I S C U S S I O N
Summary of main results
In this update of our systematic review and meta-analysis, we
found only small benefits of oral or transdermal opioids being
more effective compared with placebo in terms of pain relief and
improvement of function in people with osteoarthritis. If partici-
pants received opioids for more than four weeks, benefits on pain
relief were even further reduced. The occurrence of adverse events
often caused participants to stop taking the opioids, which is likely
to limit the usefulness of opioids in the long term. The poten-
tially higher risk of serious adverse events and substance addiction
might further limit their use. The reporting of safety outcomes was
incomplete and adverse events were reported in only about half
of the trials, and serious adverse events in three trials only. Trials
that did report safety outcomes consistently observed a significant
increase in the risk of adverse events with opioid use.
Quality of the evidence
Most of the trials were funded by the pharmaceutical industry
and we did not have enough data to explore whether the type of
funding was associated with the estimated treatment effects. We
found larger benefits on pain relief in studies with opioid use for
less than four weeks compared with longer treatments, but not
dependence of benefits on function or safety outcomes according
to treatment duration. Thus, the effectiveness of opioids may drop
during chronic use as the analgesic effects of opioids are mediated
through opioids receptors, but safety concerns were not affected
by this. The relatively low dose of morphine equivalents (median
daily dose 67 mg) administered in the included trials might pro-
vide an explanation of the small benefits observed as compared
with other studies (Maier 2002). Our ability to provide a reliable
assessment of dose dependency might have been hampered by the
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generally low morphine equivalent doses used and the lack of in-
dividual participant data. The generally used distinction between
weak and strong opioids can be misleading, because the analgesic
potency depends also on the dosage. Thus, we calculated mor-
phine equivalence doses to be able to compare different opioids,
but found no evidence for dose-dependent effects. We found little
evidence that stronger opioid agents or higher doses of these agents
will result in larger treatment effects. However, it is possible that
type of opioids interacts with dosage. For instance, higher doses
could have larger treatment effects for stronger but not for weaker
opioids. The characteristics of the trials included in our review did
not allow us to explore such interaction properly.
Data on risks of addiction due to opioid therapy is scarce, and
currently available trials are not designed to evaluate these issues.
There is a clear need for additional randomised trials and obser-
vational studies using longer follow-up times to address the risks
of substance dependence associated with different opioids. In this
systematic review, only three out of 22 trials reported measures of
withdrawal symptoms (Langford 2006; Afilalo 2010; Katz 2010).
Similar to previous systematic reviews of randomised trials on opi-
oids therapy for non-cancer pain (Kalso 2004; Furlan 2006), we
found thatmost of the trials included in our reviewhad a treatment
duration of several days or a few weeks only. Although some of the
newer trials in the update had slightly longer treatment durations
(Afilalo 2010; Breivik 2010; NCT00486811; NCT00980798),
in none of the trials did participants receive opioids for longer
than six months. This is still too short to address the impact of
opioid treatment on routine clinical practice in the treatment of
a chronic condition such as osteoarthritis. While no evidence of
long-term effects is available from randomised trials, observational
studies indicate that long-term treatment with opioids of chronic
conditions such as osteoarthritis may have deleterious effects and
do not seem to improve pain relief (Eriksen 2006).
Potential biases in the review process
We based our review on a broad literature search. Even though
we cannot exclude potential publication bias, it seems rather un-
likely that we missed relevant trials (Egger 2003). Two review
authors independently performed selection of trials and data ex-
traction to minimise bias and transcription errors (Egger 2001;
Gøtzsche 2007). The most recent systematic review on opioids
for osteoarthritis (Avouac 2007), updated in October 2006, con-
sidered 18 studies that compared opioids with placebo. We in-
cluded data from six of these in our meta-analysis and data from
four additional trials (Kjaersgaard-Andersen 1990; Quiding 1992;
Matsumoto 2005; Kivitz 2006). We excluded six trials with tra-
madol as the experimental intervention andone trial thatwas likely
to have included only a minority of people with osteoarthritis.
In our update, we identified 12 additional trials, of which three
are unpublished. In conclusion, we are likely to have included all
relevant trials in our systematic review.
Agreements and disagreements with other
studies or reviews
We excluded tramadol from our review to avoid overlap with
another Cochrane review that focused on this specific opioid in
osteoarthritis (Cepeda 2006). Extracted pain and function out-
comes and follow-up time in the previous systematic review about
opioids for osteoarthritis (Avouac 2007) were similar to our sys-
tematic review. Comparing opioids with placebo controls, Avouac
2007 found a large pooled effect for pain intensity (SMD -0.79,
95% CI -0.98 to -0.59) and a moderate pooled effect for function
(SMD -0.31, 95% CI -0.39 to -0.24). These effects are consis-
tent with our results for function but are substantially larger for
pain reduction. This discrepancy might be due to the exclusion
of some trials in our systematic review and to inclusion of newer
trials in our update in 2012. Avouac 2007 reported moderate-to-
large effects of tramadol for pain, between -0.36 to -0.93 SDunits,
in several large trials and unrealistically large beneficial effects on
pain intensity in an oxycodone trial that was excluded from our
review due to the likely very low percentage of participants with
knee or hip osteoarthritis (Roth 2000). These trials often did not
report function outcomes and could not, therefore, contribute to
the pooled analysis, or they reported considerably smaller effects
for function than for pain (Avouac 2007). In line with other stud-
ies, we found that adverse events occurring in participants treated
with opioids often caused withdrawals and drop-outs (Kalso 2004;
Furlan 2006; Avouac 2007; Gehling 2011). Tramadol may be sim-
ilar to, or even more effective than, the opioids evaluated in our
review in reducing pain and improving function, but safety con-
cerns have to be addressed further (Cepeda 2006).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Opioids decrease pain intensity and improve function but the ben-
efits observed are small. Dose increases do not appear to result in
further pain reduction, while prolongation of treatment duration
resulted in even smaller pain reduction. Observed effects for pain
were of questionable clinical relevance since the 95% confidence
intervals did not include the minimal clinically important differ-
ence of 0.37 standardised mean differences (SMDs), which corre-
sponds to 0.9 cm on a 10-cm visual analogue scale (VAS) (Wandel
2010; Rutjes 2012). The occurrence of adverse events caused one
in 20 participants to stop taking the preparations, which is likely to
limit their usefulness in the long-term treatment of osteoarthritis
of the hip or knee. The higher risk of serious adverse events and
the occurrence of addiction to opioid therapy might further limit
their clinical use, although evidence is limited by the short dura-
tion of follow-up of the studies assessing these outcomes. Never-
theless, use of opioids might be warranted in special situations,
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such as for short-term treatment of later stage osteoarthritis await-
ing surgery. However, clinicians should inform participants about
the substantial risks and only small benefits of opioid treatment
and therapeutic alternatives.
Implications for research
The effectiveness and safety of opioid and non-opioid analgesics
in participants with inadequate pain relief should be directly com-
pared in appropriately powered randomised controlled trials ac-
companied by separate Cochrane reviews or reviews of reviews in-
cluding network meta-analyses, which integrate direct and indi-
rect evidence in one single analysis while maintaining randomi-
sation (Caldwell 2005). The evidence of the effectiveness and sa-
fety of opioid therapy is mainly from a few short-term trials, de-
spite the fact that the underlying condition is chronic and requires
safe, long-term treatments (Kalso 2004; Furlan 2006). Further
long-term observational studies would increase our understand-
ing of their long-term effectiveness, safety, and the potential for
addiction. In addition, future trials might be performed in partic-
ipants with clear failures of previous analgesic therapies with non-
steroidal anti-inflammatory drugs or opioids andmight target spe-
cial subgroups, such as separately study and report participants
with knee or hip osteoarthritis to acknowledge the different mech-
anisms resulting in pain in these two phenotypes, or participants
with and without pain sensitisation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Afilalo 2010
Methods Randomised controlled trial
3-arm parallel group design
Trial duration: 17 weeks
Randomisation stratified according by centre
Multicentre trial with 112 centres
Power calculation reported
Participants Participants with moderate-to-severe joint pain who needed analgesics for at least 3
months and were dissatisfied with their current treatment were eligible
1030 participants were randomised
1023 participants with knee osteoarthritis were reported at baseline
Affected joints: 1023 knees
Number of females: 618 of 1023 (60%)
Mean age: 58 years
Mean BMI: 34 kg/m2
Interventions Experimental interventions
Oral extended-release tapentadol, 100-250 mg twice daily
Oral controlled-release oxycodone, 20-50 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 15 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 17 weeks
Extracted function outcome: WOMAC disability subscore after 17 weeks
Primary outcome: change in mean pain intensity
Notes Sponsor: Johnson & Johnson, Grünenthal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was based on
a computer-generated randomization list,
balanced using permuted blocks, and strat-
ified by study site”
Allocation concealment (selection bias) Low risk Quote: “Randomization was implemented
through an interactive voice response sys-
tem (IVRS) to dispense blinded studymed-
ication. Placebo tablets and capsules (one
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Afilalo 2010 (Continued)
for each active treatment) were used to
maintain blinded treatments. Investigators
were not provided with the randomization
codes, and the schedule was maintained
with the IVRS. The blinding was not bro-
ken until all participants had completed the
trial, except in the case of a suspected unex-
pected serious adverse reaction or if emer-
gency treatment required knowledge of a
patient’s treatment status”
Described as double-blind? Low risk Quote: “This was a randomized, double-
blind, active- and placebo controlled, par-
allel-arm, multicentre, phase III study...”
Blinding of patients? Low risk Because the study was described as a dou-
ble-dummy, we considered participants to
be blinded
Quote: “Placebo tablets and capsules (one
for each active treatment) were used to
maintain blinded treatments”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
High risk Quote: “Placebo tablets and capsules (one
for each active treatment)…”
Double-dummy technique used? Low risk Quote: “Placebo tablets and capsules (one
for each active treatment) were used to
maintain blinded treatments”
Intention-to-treat analysis performed?
Pain
High risk 2 of 346 participants excluded in experi-
mental group. 171 of 339 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
High risk 197 of 346 participants excluded in exper-
imental group, 260 of 339 participants ex-
cluded in control group
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Breivik 2010
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 28 weeks
Multicentre trial with 19 centres
Power calculation reported
Participants Participants with insufficient relief of moderate-to-severe osteoarthritis pain using
NSAIDs or COXIBs and without previous exposure to opioids were eligible
199 participants were randomised
199 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 126 knees, 73 hips
Number of females: 136 of 199 (68%)
Mean age: 63 years
Interventions Experimental intervention
Transdermal buprenorphine (Norspan; BuTrans), 5-20 µg/hour
Control intervention
Placebo, change of patch every 7 days
Treatment duration: 24 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: WOMAC pain subscore after 28 weeks
Extracted function outcome: WOMAC disability subscore after 28 weeks
Primary outcome: WOMAC pain
Notes Sponsor: Norpharma, Mundipharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisationwas performed us-
ing a validated computer system that auto-
mates the random assignment of subjects
to randomisation numbers”
Allocation concealment (selection bias) Low risk Quote: Coded-drugs of identical appear-
ance: drugs “were identical in appearance,
packed in a labelled foil pouch, contain-
ing coded treatment group identification.
The medication codes were not available
until the completion of the study and clin-
ical database lock, except in case of emer-
gency.” Also: “The randomisation schedule
was filed in a secure location in a manner
such that blindingwas properlymaintained
throughout the study”
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Breivik 2010 (Continued)
Described as double-blind? Low risk Quote: “This was a 6 months (24
weeks; 168 days), randomised, double-
blind, placebo-controlled, parallel-group,
multicentre study”
Blinding of patients? Low risk Because medication was described as iden-
tical and participants were explicitly de-
scribed as blinded, we considered partici-
pants to be blinded
Quote: “All patients, investigators, and
study centre and Sponsor personnel were
blinded to the medication codes”
Blinding of physicians? Low risk Quote: “All patients, investigators, and
study centre and Sponsor personnel were
blinded to the medication codes”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: drugs “were identical in appear-
ance, packed in a labelled foil pouch, con-
taining coded treatment group identifica-
tion. The medication codes were not avail-
able until the completion of the study and
clinical database lock, except in case of
emergency”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 5 of 100 participants excluded in experi-
mental group, 0 of 99participants excluded
in control group
Intention-to-treat analysis performed?
Function
High risk 6 of 100 participants excluded in experi-
mental group, 3 of 99participants excluded
in control group
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Caldwell 2002
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Multicentre trial
No power calculation reported
Participants Participants with prior suboptimal analgesic response to NSAIDs/paracetamol or previ-
ous intermittent opioid therapy were eligible
295 participants with knee or hip (or both) osteoarthritis were reported at baseline
Number of females: 184 of 295 (62%)
Mean age: 62 years
Interventions Experimental interventions
Oral morphine (Avinza), 30 mg once daily in the morning
Oral morphine (Avinza), 30 mg once daily in the evening
Oral morphine sulphate (Contin), 15 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: WOMAC OA index
Notes Sponsor: Elan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors’ description of the randomi-
sation process does not explain how they
generated the random sequence of alloca-
tion
Quote: “Eligible participants entered a
washout period of up to seven days and
were subsequently randomized to one of
four treatments”
Allocation concealment (selection bias) Unclear risk The authors’ description of the randomisa-
tion process does not explain whether the
random sequence of allocation was con-
cealed from study personnel responsible for
participant recruitment
Quote: “Eligible participants entered a
washout period of up to seven days and
were subsequently randomized to one of
four treatments”
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Caldwell 2002 (Continued)
Described as double-blind? Low risk Quote: “The double-blind trial was a 4-
week, multicenter, randomized, double-
blind, double-dummy, placebo controlled,
parallel trial”
Blinding of patients? Low risk Because the study was described as a dou-
ble-dummy, we considered participants to
be blinded
Quote: “Placebo Avinza and placebo
MSC [morphine sulphate controlled-re-
lease] matched the appearance of the re-
spective active treatments. Avinza capsules
and encapsulatedMSC tablets did not look
identical; therefore, to maintain the study
blind, all participants consumed two cap-
sules (one each representing Avinza and
MSC) every morning and evening (Table
1)”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
High risk Quote: “Placebo Avinza and placebo MSC
matched the appearance of the respec-
tive active treatments. Avinza capsules and
encapsulated MSC tablets did not look
identical; therefore, to maintain the study
blind, all participants consumed two cap-
sules (one each representing Avinza and
MSC) every morning and evening”
Double-dummy technique used? Low risk Quote: “Placebo Avinza and placebo MSC
matched the appearance of the respec-
tive active treatments. Avinza capsules and
encapsulated MSC tablets did not look
identical; therefore, to maintain the study
blind, all participants consumed two cap-
sules (one each representing Avinza and
MSC) every morning and evening”
Intention-to-treat analysis performed?
Pain
High risk Not all participants randomised were anal-
ysed
Quote: “Efficacy and safety analyses for
both trials were performed on all patients
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Caldwell 2002 (Continued)
who received at least one dose of studymed-
ication”
Intention-to-treat analysis performed?
Function
High risk Not all participants randomised were anal-
ysed
Quote: “Efficacy and safety analyses for
both trials were performed on all patients
who received at least one dose of studymed-
ication”
Chindalore 2005
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Randomisation stratified according to gender
Multicentre trial with 37 centres
No power calculation reported
Participants Participants with moderate to severe hip or knee pain while taking ≥1 oral analgesic
medication were eligible
362 participants were randomised
360 participants with hip or knee osteoarthritis were reported at baseline
Number of females: 249 of 360 (69%)
Average age: 54 years
Interventions Experimental interventions
Oral oxycodone, 10 mg 4 times daily
Oral oxycodone, 2.5 mg 4 times daily, plus naltrexone 0.001 mg 4 times daily (Oxytrex)
Oral oxycodone, 2.5 mg 4 times daily, plus natronex 0.001 mg twice daily (Oxytrex)
Control intervention
Placebo, twice daily
Treatment duration: 3 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: pain intensity during the past 24 hours
Notes Sponsor: Pain Therapeutics
For WOMAC disability, insufficient data were reported to calculate standardised mean
differences and it was, therefore, not included in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Chindalore 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
Quote: “Qualifying patients were ran-
domly assigned and stratified by sex to 1 of
4 treatments for 3 weeks”
Allocation concealment (selection bias) Unclear risk No information provided
Described as double-blind? Low risk Quote: “This studywas a randomized, dou-
ble-blind, placebo and active-controlled
dose escalation trial”
Blinding of patients? Low risk Because the interventions were described
as indistinguishable, we considered partic-
ipants to be blinded
Quote: “All study medications were iden-
tical in appearance, and patients, site per-
sonnel, and study monitors were blinded
to treatment assignments”
Blinding of physicians? Low risk Quote: “All study medications were iden-
tical in appearance, and patients, site per-
sonnel, and study monitors were blinded
to treatment assignments”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “All study medications were iden-
tical in appearance, and patients, site per-
sonnel, and study monitors were blinded
to treatment assignments”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 1 of 310 participants (0.3%) excluded in
experimental groups, 1 of 52 participants
(1.9%) excluded in control group
Intention-to-treat analysis performed?
Function
High risk 1 of 310 participants (0.3%) excluded in
experimental groups, 1 of 52 participants
(1.9%) excluded in control group
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Etropolski 2011
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 8 weeks
Randomisation stratified according to study centre
Multicentre trial with 84 centres
No power calculation reported
Participants Participants with joint disease requiring surgery and insufficient pain relief by stable
analgesic regimens were eligible
598 participants were randomised
598 participants with knee or hip osteoarthritis reported at baseline
Number of females: 349 of 596 (59%)
Mean age: 59 years
Interventions Experimental interventions
Oral immediate-release tapentadol, 50 mg 3-6 times daily
Oral immediate-release tapentadol, 75 mg 3-6 times daily
Oral immediate-release oxycodone, 10 mg 3-6 times daily
Control intervention
Placebo, 3-6 times daily
Treatment duration: 2 weeks
Analgesics other than study drugs allowed and intake was similar between groups
Outcomes Extracted pain outcome: global pain after 8 weeks
No function outcome reported
Primary outcome: change in pain intensity
Notes Sponsor: Johnson & Johnson
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was based on a
computer-generated randomization sched-
ule, stratified by study center, and imple-
mented using an interactive voice response
system”
Allocation concealment (selection bias) Low risk Quote: “Randomization was based on a
computer-generated randomization sched-
ule, stratified by study center, and imple-
mented using an interactive voice response
system”
Described as double-blind? Low risk Quote: “In this double-blind study, pa-
tients with end-stage joint disease were ran-
domized to tapentadol IR (50mgor 75mg)
, oxycodone HCL IR 10 mg, or placebo”
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Etropolski 2011 (Continued)
Blinding of patients? Low risk Quote: “All study drugs were provided as
overencapsulated tablets or capsules and
were identical in shape, color, and size”
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Masking:
Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor)”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “All study drugs were provided as
overencapsulated tablets or capsules and
were identical in shape, color, and size”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 2 of 306 participants excluded in experi-
mental group, 74 of 148 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Fidelholtz 2011
Methods Randomised controlled trial
4-arm parallel group design
Trial duration unclear
Multicentre trial with 99 centres
No power calculation reported
Participants Participants with moderate-to-severe osteoarthritis pain of knees or hips were eligible
Interventions Experimental intervention
Oral oxycodone, 10-40 mg twice daily
Control intervention
Placebo
Treatment duration: not reported
Unclear whether analgesics other than study drugs allowed
Outcomes Extracted pain outcome: WOMAC pain subscore after 8 weeks
No function outcome reported
Primary outcome: WOMAC pain
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Fidelholtz 2011 (Continued)
Notes Sponsor: Pfizer, Pain Solutions
2 trial arms excluded from review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “A randomized, double-blind,
placebo (PBO)- & active-controlled study.
..”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrial.gov: “Double
Blind (Subject, Caregiver, Investigator,
Outcomes Assessor)”
Blinding of outcome assessors? Unclear risk Because outcomes were self reported, and
because it was unclear whether partici-
pants were properly blinded, it was unclear
whether outcome assessors were blinded
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Unclear risk Description of intervention is not detailed
enough to assess whether double-dummy
technique was used
Intention-to-treat analysis performed?
Pain
Unclear risk It was unclear how many participants were
randomised in this study, so it was not pos-
sible to assess whether all participants ran-
domised were included in the analysis
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
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Friedmann 2011
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 14 weeks
Multicentre trial with 61 centres
Power calculation reported
Participants Participants with moderate-to-severe osteoarthritis pain using NSAIDs or opioids were
eligible
412 participants were randomised
412 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 323 knees and 89 hips
Number of females: 288 of 412 (70%)
Mean age: 58 years
Interventions Experimental intervention
Oral extended-release oxycodone (Remoxy), 5-20 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 12 weeks
Unclear whether analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 14 weeks
No function outcome reported
Primary outcome: change in pain intensity score
Notes Sponsor: Pain Therapeutics, King, Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “...a double-blind, multicenter,
placebo-controlled trial...”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
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Friedmann 2011 (Continued)
Blinding of outcome assessors? Unclear risk Because outcomes were self reported, and
because it was unclear whether partici-
pants were properly blinded, it was unclear
whether outcome assessors were blinded
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Unclear risk Description of intervention is not detailed
enough to assess whether double-dummy
technique was used
Intention-to-treat analysis performed?
Pain
High risk 2 of 205 participants excluded in exper-
imental group, 0 of 207 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Hartrick 2009
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 2 weeks
Randomisation stratified according to study centre
Multicentre trial
Power calculation reported
Participants Participants with insufficient relief of moderate-to-severe osteoarthritis pain who were
candidates for joint replacement surgery were eligible
674 participants were randomised
659 participants with knee or hip osteoarthritis were reported at baseline
Number of females: 324 of 659 (49%)
Mean age: 61 years
Mean BMI: 33 kg/m2
Interventions Experimental interventions
Oral immediate-release tapentadol, 50 mg every 4-6 hours
Oral immediate-release tapentadol, 75 mg every 4-6 hours
Oral oxycodone, 10 mg every 4-6 hours
Control intervention
Placebo, every 4-6 hours
Treatment duration: 1 week
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
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Hartrick 2009 (Continued)
Outcomes Extracted pain outcome: global pain after 2 weeks
No function outcome reported
Primary outcome: sum of pain intensity difference
Notes Sponsor: Johnson & Johnson, Grünenthal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted blocks were used to balance the
number of participants across groups, so
generation of sequence of random alloca-
tion was likely computer-generated
Allocation concealment (selection bias) Unclear risk No information on concealment of alloca-
tion was provided, so risk of selection bias
was unclear
Described as double-blind? Low risk Quote: “...randomized, double-blind, ac-
tive- and placebo-controlled study...”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “This is a
double-blind study, i.e., neither patients
nor investigators will know what treatment
is given”
Blinding of outcome assessors? Unclear risk Because outcomes were self reported, and
because it was unclear whether partici-
pants were properly blinded, it was unclear
whether outcome assessors were blinded
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 0 of 330 participants excluded in experi-
mental group, 86 of 172 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
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Katz 2010
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 14 weeks
Randomisation stratified according to joint (hip/knee), daily dosage at end of titration,
and study site
Multicentre trial with 81 centres
Power calculation reported
Participants Participants with insufficient pain relief with non-opioids analgesics, tramadol, or other
opioids at ≤ 40-mg morphine equivalent per day were eligible
344 participants were randomised
344 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 267 knees and 77 hips
Number of females: 201 of 344 (58%)
Mean age: 54 years
Mean BMI: 32 kg/m2
Interventions Experimental intervention
Oral morphine sulphate and naltrexone hydrochloride (EMBEDA), 20-80 mg twice
daily
Control intervention
Placebo, twice daily
Treatment duration: 12 weeks
Analgesics other than study drugs allowed and intake was similar between groups
Outcomes Extracted pain outcome: global pain after 14 weeks
Extracted function outcome: WOMAC disability subscore after 14 weeks
Primary outcome: change in average pain intensity
Notes Sponsor: King, Quintiles Medical Communications, Alphapharm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Low risk Quote: “The outpatient site contacted the
InteractiveWebResponse System to receive
a randomization number and treatment as-
signment”
Described as double-blind? Low risk Quote: “This randomized, double-blind,
placebo-controlled, multicenter outpatient
study”
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Katz 2010 (Continued)
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of outcome assessors? Unclear risk Because outcomes were self reported, and
because it was unclear whether partici-
pants were properly blinded, it was unclear
whether outcome assessors were blinded
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Unclear risk Unclear whether double-dummy tech-
nique was used
Intention-to-treat analysis performed?
Pain
High risk 1 of 171 participants excluded in exper-
imental group, 0 of 173 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis
Kivitz 2006
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 2 weeks
Multicentre trial
Power calculation reported
Participants Participants with suboptimal analgesic response to NSAIDs/paracetamol or previous
opioid therapy were eligible
370 participants were randomised
370 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 297 knees and 73 hips
Number of females: 224 of 370 (61%)
Interventions Experimental interventions
Oral extended-release oxymorphone, 10 mg twice daily
Oral extended-release oxymorphone, 40 mg twice daily
Oral extended-release oxymorphone, 50 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 2 weeks
No analgesics other than study drugs allowed
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Kivitz 2006 (Continued)
Outcomes Extracted pain outcome: global pain after 2 weeks
Extracted function outcome: WOMAC disability subscore after 2 weeks
Primary outcome: change in pain intensity
Notes Sponsor: Endo Pharmaceuticals Inc, Penwest Pharmaceuticals Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated random-
ization schedule was used to assign them to
1 of 4 groups”
Allocation concealment (selection bias) Low risk Quote: “The study medications had com-
puter-generated 2-part labels. One part of
the label, which contained study and pa-
tient information, was attached to the box
that contained all 4 bottles of study med-
ication. The other part of the label was a
tear-off section containing the same infor-
mation. This tear-off section was removed
at the time of dispensing and was attached
to the appropriate page of the case report
form; a copy of this page was made and re-
tained in the investigator’s study file. The
treatment to which a patient had been as-
signed was concealed by an alcohol-remov-
able-ink overlay on the tear-off part of the
label”
Described as double-blind? Low risk Quote: “This was a 2-week, multicenter,
randomized, double-blind, parallel-group,
dose-ranging, Phase lll trial”
Blinding of patients? Low risk Because the study was described as a dou-
ble-dummy, we considered participants to
be blinded
Quote: “Study medications were overen-
capsulated in gelatin capsules so they were
visually indistinguishable, and they were
administered in a double-dummy fashion
to maintain blinding”
Blinding of physicians? Low risk Quote: “The study patients, study person-
nel, and investigators were blinded to the
identity of the study treatments”
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Kivitz 2006 (Continued)
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
High risk The authors reported that interventions
were only visually indistinguishable, which
is probably the reason why double-dummy
was implemented
Quote: “Study medications were overen-
capsulated in gelatin capsules so they were
visually indistinguishable, and they were
administered in a double-dummy fashion
to maintain blinding”
Double-dummy technique used? Low risk Quote: “Study medications were overen-
capsulated in gelatin capsules so they were
visually indistinguishable, and they were
administered in a double-dummy fashion
to maintain blinding”
Intention-to-treat analysis performed?
Pain
High risk 9 of 279 participants (0.7%) excluded in
experimental groups, 4 of 91 participants
(4.4%) excluded in control group
Intention-to-treat analysis performed?
Function
High risk 9 of 279 participants (0.7%) excluded in
experimental groups, 4 of 91 participants
(4.4%) excluded in control group
Kjaersgaard-Andersen 1990
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Multicentre trial with 7 centres
Power calculation reported
Participants Participants with chronic pain requiring analgesic treatment were eligible
158 participants with hip osteoarthritis were reported at baseline
Affected joints: 158 hips
Number of females: 72 of 158 (46%)
Mean age: 66 years
Mean BMI: 26 kg/m2
Interventions Experimental intervention
Oral codeine 60 mg plus paracetamol 1000 mg, 3 times daily
Control intervention
Paracetamol 1000 mg, 3 times daily
Treatment duration: 4 weeks
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Kjaersgaard-Andersen 1990 (Continued)
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: participant’s global assessment after 4 weeks
Notes No information about source of funding provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “The study was designed as a ran-
domised, double-blind and parallel inves-
tigation”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “The tablets were identical in
weight, appearance and taste”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “The tablets were identical in
weight, appearance and taste”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 43 of 83 participants (52%) excluded in
experimental group, 18 of 75 participants
(24%) excluded in control group
Intention-to-treat analysis performed?
Function
High risk 40 of 83 participants (48%) excluded in
experimental group, 15 of 75 participants
(20%) excluded in control group
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Langford 2006
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 8 weeks
Randomisation stratified according to target joint (knee/hip)
Multicentre trial
Power calculation reported
Participants Participants without adequate pain control under weak opioid treatment (with and
without paracetamol) were eligible
416 participants were randomised
399 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 211 knees and 188 hips
Number of females: 265 of 399 (66%)
Interventions Experimental intervention
Transdermal fentanyl (Durogesic), median dosage 25 µg/hour
Control intervention
Placebo
Treatment duration: 6 weeks
Analgesics other than study drugs allowed and intake assessed, but it was unclear whether
intake was similar between groups
Outcomes Extracted pain outcome: global pain after 8 weeks
Extracted function outcome: WOMAC disability subscore after 8 weeks
Primary outcome: pain relief on VAS
Notes Sponsor: Janssen-Cilag
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas performedus-
ing a computer-generated list”
Allocation concealment (selection bias) Low risk Quote: “Participants were assigned con-
secutive treatment codes, and investigators
were unaware of the treatment allocation”
Described as double-blind? Low risk Quote: “The aim of the present trial was
therefore to assess pain relief from treat-
ment with TDF [transdermal fentanyl] as
compared with placebo in a double-blind
study”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
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Langford 2006 (Continued)
Quote: “TDF and placebo patches were
identical”
Blinding of physicians? Low risk Quote: “investigators were unaware of the
treatment allocation”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “TDF and placebo patches were
identical”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk No information on exclusions available
Intention-to-treat analysis performed?
Function
High risk No information on exclusions available
Markenson 2005
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 13 weeks
Multicentre trial with 9 centres
Power calculation reported
Participants Participants with moderate-to-severe pain while taking NSAIDs/paracetamol, with con-
traindications to NSAID therapy or with previous oral opioid therapy were eligible
109 participants were randomised
107 participants with osteoarthritis were reported at baseline
Affected joints: 33 knees, 19 hips, and 57 other joints
Number of females: 78 of 107 (73%)
Mean age: 63 years
Interventions Experimental intervention
Oral oxycodone (OxyContin), 10 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 13 weeks
Analgesics other than study drugs allowed and intake assessed, but it was unclear whether
intake was similar
Outcomes Extracted pain outcome: global pain after 13 weeks
Extracted function outcome: WOMAC global scale after 13 weeks
Notes Sponsor: Purdue Pharma
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Markenson 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The computer-generated random-
ization code and study drug bottles la-
beled with randomization numbers were
supplied by the sponsor”
Allocation concealment (selection bias) Low risk Quote: “The computer-generated random-
ization code and study drug bottles la-
beled with randomization numbers were
supplied by the sponsor”
Described as double-blind? Low risk Quote: “This was a double blind, random-
ized, placebo-controlled, parallel-group
study”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “Patients who met the entry crite-
ria were randomly assigned in double blind
fashion to receive either 10-mg tablets of
CR oxycodone or matching placebo every
12 hours”
Blinding of physicians? Low risk Because coded labelled bottles were pro-
vided by sponsor and drug tables were
matching the placebo tablets, physicians
were considered blinded as well
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “Patients who met the entry crite-
ria were randomly assigned in double blind
fashion to receive either 10-mg tablets
of CR [controlled release] oxycodone or
matching placebo every 12 hours”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 2 randomised participants who withdrew
before receiving treatment were excluded
from the analyses
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Markenson 2005 (Continued)
Intention-to-treat analysis performed?
Function
High risk 2 randomised participants who withdrew
before receiving treatment were excluded
from the analyses
Matsumoto 2005
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Simple randomisation
Multicentre trial
Power calculation reported
Participants Participants with suboptimal analgesic response to NSAIDs, paracetamol, or opioids
were eligible
491 participants were randomised
489 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 373 knees and 116 hips
Number of females: 297 of 489 (61%)
Mean age: 62 years
Mean BMI: 34 kg/m2
Interventions Experimental interventions
Oral extended-release oxymorphone, 20 mg twice daily
Oral extended-release oxymorphone, 40 mg twice daily
Oral controlled-release oxycodone, 20 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: WOMAC pain subscore after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: change in arthritis pain intensity
Notes Sponsors: TheraQuest Biosciences, Endo Pharmaceuticals, Penwest Pharmaceuticals Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The list of randomization num-
bers was based on a computer generated
randomization schedule”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
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Matsumoto 2005 (Continued)
Described as double-blind? Low risk Quote: “The study was a multicenter, 4-
week, randomized, double-blind, parallel-
group study”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “Active study medication tablets
were overencapsulated and visually indis-
tinguishable from each other and from the
placebo tablets”
Blinding of physicians? Low risk Quote: “Study enrollees, study personnel,
and investigators were blinded to the iden-
tity of the treatments”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “Active study medication tablets
were overencapsulated and visually indis-
tinguishable from each other and from the
placebo tablets”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 19 of 367 participants (5.2%) excluded in
experimental groups, 5 of 124 (4.0%) par-
ticipants excluded in control group
Intention-to-treat analysis performed?
Function
High risk 19 of 367 participants (5.2%) excluded in
experimental groups, 5 of 124 (4.0%) par-
ticipants excluded in control group
Munera 2010
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Multicentre trial with 25 centres
Power calculation reported
Participants Participants with inadequate pain control using NSAIDs were eligible
315 participants were randomised
315 participants with knee or hip osteoarthritis were reported at baseline
Affected joints: 173 knees and 142 hips
Number of females: 212 of 315 (67%)
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Munera 2010 (Continued)
Mean age: 61 years
Interventions Experimental intervention
Transdermal buprenorphine, 5, 10, or 20 µg/hour
Control intervention
Placebo
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: participant’s global assessment after 4 weeks
Primary outcome: percentage of participants considered to have achieved treatment
success
Notes Sponsor: Purdue
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “…randomized,
placebo-controlled, double-blind, parallel-
group investigation”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “Placebo
TDS [transdermal buprenorphine]-treated
patients received identical-looking patches
for each strength level”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
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Munera 2010 (Continued)
Interventions reported as indistinguish-
able?
Low risk Quote: “Placebo TDS-treated patients re-
ceived identical-looking patches for each
strength level”
Double-dummy technique used? Unclear risk No information provided
Intention-to-treat analysis performed?
Pain
High risk 3 of 152 participants excluded in exper-
imental group, 1 of 163 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
High risk 3 of 152 participants excluded in exper-
imental group, 1 of 163 participants ex-
cluded in control group
NCT00486811
Methods Randomised controlled trial
3-arm parallel group design
Trial duration unclear
Multicentre trial with 101 centres
No power calculation reported
Participants Participants who were dissatisfied with their prior analgesic therapy were eligible
987 participants with knee osteoarthritis were reported at baseline
Number of females: 707 of 987 (72%)
Mean age: 62 years
Interventions Experimental interventions
Oral extended-release tapentadol, 100-250 mg twice daily
Oral controlled-release oxycodone, 20-50 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 15 weeks
Unclear whether analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 15 weeks
Extracted function outcome: WOMAC global scale after 15 weeks
Primary outcome: change in mean pain intensity
Notes Sponsor: Grünenthal GmbH
Risk of bias
Bias Authors’ judgement Support for judgement
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NCT00486811 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of outcome assessors? Unclear risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Unclear risk No information provided
Intention-to-treat analysis performed?
Pain
Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk It was unclear whether all participants ran-
domised were also analysed
NCT00531427
Methods Randomised controlled trial
2-arm parallel group design
Trial duration unclear
Multicentre trial with 83 centres
No power calculation reported
Participants Participants with suboptimal analgesic response to opioids were eligible
570 participants were randomised
570 participants with knee osteoarthritis were reported at baseline
Affected joints: 567 knees
Number of females: 356 of 567 (63%)
Mean age: 59 years
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NCT00531427 (Continued)
Interventions Experimental intervention
Transdermal buprenorphine, 10 or 20 µg/hour
Control intervention
Placebo
Treatment duration: 12 weeks
Analgesics other than study drugs allowed and intake was similar between groups
Outcomes Extracted pain outcome: global pain after 12 weeks.
No function outcome reported
Primary outcome: mean pain over the last 24 hours
Notes Sponsor: Purdue Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of outcome assessors? Unclear risk Because it was unclear whether participants
were blinded and outcomes were partici-
pant-reported, the risk of detectionbiaswas
considered unclear
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Unclear risk No information provided
Intention-to-treat analysis performed?
Pain
Low risk All randomised participants included in the
analysis
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NCT00531427 (Continued)
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
NCT00980798
Methods Randomised controlled trial
2-arm parallel group design
Trial duration unclear
Power calculation reported
Participants Participants with insufficient pain relief using NSAIDs, paracetamol, or a weak opioid
were eligible
88 participants with knee or hip osteoarthritis were reported at baseline
Number of females: 208 of 288 (72%)
Mean age: 65 years
Interventions Experimental intervention
Oral hydromorphone (OROS), 4-32 mg once daily
Control intervention
Placebo, once daily
Treatment duration: 16 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 16 weeks
No function outcome reported
Primary outcome: mean pain (Item 5 of Brief Pain Inventory)
Notes Sponsor: Janssen-Cilag
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Caregiver, Investigator,
Outcomes Assessor)”
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NCT00980798 (Continued)
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote from ClinicalTrials.gov: “the con-
trol group receives an optically identical
tablet with no active ingredient, a so-called
placebo.”
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Caregiver, Investigator,
Outcomes Assessor)”
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote from ClinicalTrials.gov: “the con-
trol group receives an optically identical
tablet with no active ingredient, a so-called
placebo”
Double-dummy technique used? Unclear risk No information available
Intention-to-treat analysis performed?
Pain
High risk 13 randomised participants were excluded
from the analyses
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Peloso 2000
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Multicentre trial with 4 centres
Power calculation reported
Participants Participants with osteoarthritis symptoms requiring therapy with paracetamol, anti-in-
flammatory agents or opioids were eligible
103 participants were randomised
103 participants with osteoarthritis were reported at baseline
Affected joints: 94 knees and 49 hips
Number of females: 64 of 103 (62%)
Mean age: 62 years
Mean BMI: 34 kg/m2
Mean disease duration: 10.3 years
65Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Peloso 2000 (Continued)
Interventions Experimental intervention
Oral codeine (Contin), 100 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
Analgesics other than study drugs allowed and intake assessed, but it was unclear whether
intake was similar between groups
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: WOMAC pain and overall pain intensity
Notes Sponsor: Purdue Frederick
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “Randomized, balanced, double
blind parallel group assignment”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “identical appearing placebo”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “identical appearing placebo”
Double-dummy technique used? High risk No double-dummy technique used
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Peloso 2000 (Continued)
Intention-to-treat analysis performed?
Pain
High risk 20 of 51 participants (39%) excluded in
experimental group, 17 of 52 participants
(33%) excluded in control group
Intention-to-treat analysis performed?
Function
High risk 20 of 51 participants (39%) excluded in
experimental group, 17 of 52 participants
(33%) excluded in control group
Quiding 1992
Methods Randomised controlled trial
3-arm cross-over design
Trial duration: 1 week
No power calculation reported
Participants Participants in need of analgesic medication for hip osteoarthritis were eligible
27 participants were randomised
26 participants with hip osteoarthritis were reported at baseline
Affected joints: 26 hips
Number of females: 22 of 26 (85%)
Mean age: 53 years
Interventions Experimental intervention
Oral codeine 30 mg plus ibuprofen 200 mg, 6 times in 32 hours
Control intervention
Ibuprofen 200 mg, 6 times in 32 hours
Treatment duration: 32 hours
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 1 week
No function outcome reported
No primary outcome reported
Notes No information about source of funding provided
1 trial arm excluded from review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
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Quiding 1992 (Continued)
Described as double-blind? Low risk Quote: “double-blind, placebo-controlled
cross-over design”
Blinding of patients? Low risk Because the study was described as a dou-
ble-dummy, we considered participants to
be blinded
Quote: “a double-dummy technique was
used to ensure blindness of the study”
Blinding of physicians? Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? Low risk Quote: “a double-dummy technique was
used to ensure blindness of the study”
Intention-to-treat analysis performed?
Pain
Unclear risk No information on exclusions available
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Shannon 2005
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 30 weeks
Multicentre trial with 41 centres
No power calculation reported
Participants Participants with moderate-to-severe pain while taking paracetamol, non-steroidal anti-
inflammatory agents or opioids were eligible
327 participants were randomised
327 participants with knee or hip osteoarthritis were reported at baseline
Number of females: 219 of 326 (67%)
Mean age: 61 years
Interventions Experimental intervention
Transdermal buprenorphine (Butrans), 5, 10 or 20 µg/hour
Control intervention
Placebo
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Shannon 2005 (Continued)
Treatment duration: 4 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 30 weeks
Extracted function outcome: after 30 weeks
Primary outcome: time to development of inadequate analgesia
Notes Sponsor: Purdue Pharma L.P
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Described as double-blind? Low risk Quote: “Randomized, double-blind,
placebo-controlled”
Blinding of patients? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of physicians? Low risk Quote from ClinicalTrials.gov: “Double
Blind (Subject, Investigator)”
Blinding of outcome assessors? Unclear risk Because it was unclear whether participants
were blinded and the outcomes are partic-
ipant-reported, the risk of bias was unclear
Interventions reported as indistinguish-
able?
High risk Interventions were not reported as indis-
tinguishable
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 1 of 165 participants excluded in exper-
imental group, 0 of 162 participants ex-
cluded in control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
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Zautra 2005
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 13 weeks
Multicentre trial with 9 centres
No power calculation reported
Participants 107 participants were randomised
104 participants with knee osteoarthritis were reported at baseline
Number of females: 76 of 104 (73%)
Mean age: 63 years
Interventions Experimental intervention
Oral oxycodone (Oxycontin), 10 mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 13 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 13 weeks
No function outcome reported
Primary outcome: coping efficacy and arthritis helplessness
Notes Sponsor: Purdue Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk Quote: “The bottles of medication were la-
beled with a randomization number and
dispensed by the investigators”
Described as double-blind? Low risk Quote: “Double-blind, randomized,
placebo-controlled, parallel-group study”
Blinding of patients? Low risk Because the study used indistinguishable
interventions, we considered participants
to be blinded
Quote: “Patients were randomized at each
of the 9 participating clinics to receive ei-
ther oral CR oxycodone (10 mg) or match-
ing placebo”
Blinding of physicians? Unclear risk No information provided
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Zautra 2005 (Continued)
Blinding of outcome assessors? Low risk Because participants were blinded and out-
comes were participant-reported, the risk
of detection bias was considered low
Interventions reported as indistinguish-
able?
Low risk Quote: “Patients were randomized at each
of the 9 participating clinics to receive ei-
ther oral CR oxycodone (10 mg) or match-
ing placebo”
Double-dummy technique used? High risk No double-dummy technique used
Intention-to-treat analysis performed?
Pain
High risk 1 of 56 participants (1.8%) excluded in ex-
perimental group, 2 of 51 participants (3.
9%) excluded in control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
BMI: body mass index; COXIB: cyclo-oxygenase inhibitor; NSAID: non-steroidal anti-inflammatory drug; VAS: visual analogue scale;
WOMAC: Western Ontario and McMaster Universities Arthritis Index.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 2006 Only active control interventions
Andrei 1984 Percentage of participants with knee or hip osteoarthritis 17% (5/30)
Boureau 1990 Only active control interventions
Boyer 2012 Cross-over trial providing pooled results only
Brooks 1982 Percentage of participants with osteoarthritis 50%, no information about joints involved
Burch 2004 Not a randomised controlled trial
Caldwell 1999 Percentage of participants with knee or hip osteoarthritis likely to be below 50%
Choquette 2008 Not a randomised controlled trial
Conaghan 2011 Only active control interventions
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(Continued)
Corsinovi 2009 Only active control interventions
Doak 1992 Cross-over trial providing pooled results only
Fancourt 1984 Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of participants with
osteoarthritis
Friedmann 2011b Percentage of participants with knee or hip osteoarthritis 15% (123/827)
Gazi 2005 Only active control interventions
Hale 2007 Only active control interventions
James 2010 Only active control interventions
Katz 2010b Only active control interventions
Le Loet 2005 Not a randomised controlled trial
McIlwain 2005 Not a randomised controlled trial
Mitchell 1984 Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of participants with
osteoarthritis
Neubauer 1983 Percentage of participants with osteoarthritis 15% (5/33)
Rosenthal 2007 Not a randomised controlled trial
Roth 2000 Percentage of participants with knee or hip osteoarthritis likely to be below 50%
Salzman 1983 Only active control interventions
Tassain 2003 Percentage of participants with osteoarthritis 7% (2/28)
Torres 2001 Not a randomised controlled trial
Vignon 1999 Comparison of combination of dextropropoxyphene, paracetamol, and caffeine with placebo
Vlok 1987 Cross-over trial providing pooled results only
Vorsanger 2011 Only active control interventions
Wallace 1994 Cross-over trial providing pooled results only
Wang 1965 Percentage of participants with osteoarthritis 6% (2/34)
Wild 2010 Only active control interventions
72Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Kroner 1991
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 3 weeks
Multicentre trial
Participants 131 participants with hip osteoarthritis were reported at baseline
Number of females: 70 of 131 (53%)
Interventions Experimental intervention
Codeine 30 mg plus paracetamol 500 mg
Control intervention
Paracetamol 500 mg
Treatment duration: 3 weeks
Outcomes Assessed efficacy outcomes: pain intensity, pain relief, participant’s evaluation of the effect of treatment
Assessed safety outcomes: number of participants withdrawn due to adverse events, serious adverse events
Notes Insufficient data provided in published abstract, no full-text article available. Awaiting author response
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D A T A A N D A N A L Y S E S
Comparison 1. Opioids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 22 8275 Std. Mean Difference (Random, 95% CI) -0.28 [-0.35, -0.20]
1.1 Buprenorphine 4 1401 Std. Mean Difference (Random, 95% CI) -0.19 [-0.30, -0.09]
1.2 Codeine 3 179 Std. Mean Difference (Random, 95% CI) -0.51 [-1.01, -0.01]
1.3 Fentanyl 1 399 Std. Mean Difference (Random, 95% CI) -0.22 [-0.42, -0.03]
1.4 Hydromorphone 1 275 Std. Mean Difference (Random, 95% CI) 0.04 [-0.19, 0.28]
1.5 Morphine 2 638 Std. Mean Difference (Random, 95% CI) -0.25 [-0.42, -0.09]
1.6 Oxycodone 10 2943 Std. Mean Difference (Random, 95% CI) -0.31 [-0.47, -0.15]
1.7 Oxymorphone 2 645 Std. Mean Difference (Random, 95% CI) -0.39 [-0.58, -0.21]
1.8 Tapentadol 4 1795 Std. Mean Difference (Random, 95% CI) -0.31 [-0.46, -0.16]
2 Function 12 3553 Std. Mean Difference (Random, 95% CI) -0.26 [-0.35, -0.17]
2.1 Buprenorphine 2 501 Std. Mean Difference (Random, 95% CI) -0.23 [-0.40, -0.05]
2.2 Codeine 2 169 Std. Mean Difference (Random, 95% CI) -0.42 [-0.74, -0.10]
2.3 Fentanyl 1 399 Std. Mean Difference (Random, 95% CI) -0.28 [-0.48, -0.09]
2.4 Morphine 2 639 Std. Mean Difference (Random, 95% CI) -0.20 [-0.38, -0.02]
2.5 Oxycodone 4 680 Std. Mean Difference (Random, 95% CI) -0.30 [-0.58, -0.01]
2.6 Oxymorphone 2 645 Std. Mean Difference (Random, 95% CI) -0.38 [-0.56, -0.19]
2.7 Tapentadol 2 520 Std. Mean Difference (Random, 95% CI) -0.15 [-0.45, 0.16]
3 Number of participants
experiencing any adverse event
10 4898 Risk Ratio (IV, Random, 95% CI) 1.49 [1.35, 1.63]
3.1 Buprenorphine 1 199 Risk Ratio (IV, Random, 95% CI) 1.25 [1.09, 1.42]
3.2 Codeine 1 66 Risk Ratio (IV, Random, 95% CI) 1.28 [0.94, 1.75]
3.3 Fentanyl 1 416 Risk Ratio (IV, Random, 95% CI) 1.55 [1.33, 1.81]
3.4 Morphine 1 344 Risk Ratio (IV, Random, 95% CI) 1.10 [0.89, 1.35]
3.5 Oxycodone 6 1779 Risk Ratio (IV, Random, 95% CI) 1.69 [1.47, 1.95]
3.6 Oxymorphone 1 304 Risk Ratio (IV, Random, 95% CI) 1.59 [1.28, 1.97]
3.7 Tapentadol 4 1790 Risk Ratio (IV, Random, 95% CI) 1.39 [1.17, 1.66]
4 Number of participants who
withdrew because of adverse
events
21 8128 Risk Ratio (IV, Random, 95% CI) 3.76 [2.93, 4.82]
4.1 Buprenorphine 4 1407 Risk Ratio (IV, Random, 95% CI) 3.10 [1.38, 6.94]
4.2 Codeine 3 277 Risk Ratio (IV, Random, 95% CI) 3.67 [2.16, 6.24]
4.3 Fentanyl 1 399 Risk Ratio (IV, Random, 95% CI) 2.63 [1.64, 4.23]
4.4 Hydromorphone 1 288 Risk Ratio (IV, Random, 95% CI) 5.51 [2.54, 11.98]
4.5 Morphine 2 639 Risk Ratio (IV, Random, 95% CI) 2.12 [0.87, 5.15]
4.6 Oxycodone 9 2653 Risk Ratio (IV, Random, 95% CI) 5.55 [3.47, 8.87]
4.7 Oxymorphone 2 674 Risk Ratio (IV, Random, 95% CI) 5.32 [2.93, 9.68]
4.8 Tapentadol 4 1791 Risk Ratio (IV, Random, 95% CI) 2.76 [1.90, 4.00]
5 Number of participants
experiencing any serious
adverse event
3 681 Risk Ratio (IV, Random, 95% CI) 3.35 [0.83, 13.56]
5.1 Codeine 1 158 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Fentanyl 1 416 Risk Ratio (IV, Random, 95% CI) 2.78 [0.57, 13.60]
5.3 Oxycodone 1 107 Risk Ratio (IV, Random, 95% CI) 6.39 [0.34, 120.71]
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6 Withdrawal symptoms 3 Odds Ratio (Random, 95% CI) 2.76 [2.02, 3.77]
6.1 Oxycodone 1 Odds Ratio (Random, 95% CI) 2.18 [0.61, 7.81]
6.2 Morphine 1 Odds Ratio (Random, 95% CI) 3.05 [0.12, 75.52]
6.3 Tapentadol 1 Odds Ratio (Random, 95% CI) 0.99 [0.25, 3.97]
6.4 Fentanyl 1 Odds Ratio (Random, 95% CI) 2.97 [2.13, 4.14]
Analysis 1.1. Comparison 1 Opioids versus placebo, Outcome 1 Pain.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 1 Pain
Study or subgroup Opioids Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Buprenorphine
Breivik 2010 95 99 -0.242 (0.144) 3.5 % -0.24 [ -0.52, 0.04 ]
Munera 2010 149 162 -0.127 (0.114) 4.2 % -0.13 [ -0.35, 0.10 ]
NCT00531427 283 287 -0.14 (0.084) 5.1 % -0.14 [ -0.30, 0.02 ]
Shannon 2005 164 162 -0.324 (0.112) 4.3 % -0.32 [ -0.54, -0.10 ]
Subtotal (95% CI) 691 710 17.2 % -0.19 [ -0.30, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.22, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00031)
2 Codeine
Kjaersgaard-Andersen 1990 40 57 -0.143 (0.207) 2.3 % -0.14 [ -0.55, 0.26 ]
Peloso 2000 31 35 -0.783 (0.256) 1.7 % -0.78 [ -1.28, -0.28 ]
Quiding 1992 8 8 -0.844 (0.525) 0.5 % -0.84 [ -1.87, 0.18 ]
Subtotal (95% CI) 79 100 4.4 % -0.51 [ -1.01, -0.01 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 4.44, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 2.00 (P = 0.046)
3 Fentanyl
Langford 2006 202 197 -0.223 (0.1) 4.7 % -0.22 [ -0.42, -0.03 ]
Subtotal (95% CI) 202 197 4.7 % -0.22 [ -0.42, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
4 Hydromorphone
NCT00980798 132 143 0.044 (0.121) 4.1 % 0.04 [ -0.19, 0.28 ]
Subtotal (95% CI) 132 143 4.1 % 0.04 [ -0.19, 0.28 ]
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Opioids Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.36 (P = 0.72)
5 Morphine
Caldwell 2002 222 73 -0.346 (0.136) 3.7 % -0.35 [ -0.61, -0.08 ]
Katz 2010 170 173 -0.195 (0.108) 4.4 % -0.20 [ -0.41, 0.02 ]
Subtotal (95% CI) 392 246 8.1 % -0.25 [ -0.42, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
6 Oxycodone
Afilalo 2010 342 168 -0.129 (0.094) 4.8 % -0.13 [ -0.31, 0.06 ]
Chindalore 2005 309 51 -0.316 (0.152) 3.3 % -0.32 [ -0.61, -0.02 ]
Etropolski 2011 143 74 -0.685 (0.147) 3.4 % -0.69 [ -0.97, -0.40 ]
Fidelholtz 2011 158 141 0 (0.116) 4.2 % 0.0 [ -0.23, 0.23 ]
Friedmann 2011 203 207 -0.263 (0.099) 4.7 % -0.26 [ -0.46, -0.07 ]
Hartrick 2009 172 86 -0.51 (0.134) 3.7 % -0.51 [ -0.77, -0.25 ]
Markenson 2005 56 51 -0.431 (0.196) 2.4 % -0.43 [ -0.82, -0.05 ]
Matsumoto 2005 120 59 -0.285 (0.159) 3.1 % -0.29 [ -0.60, 0.03 ]
NCT00486811 331 168 0.047 (0.095) 4.8 % 0.05 [ -0.14, 0.23 ]
Zautra 2005 55 49 -0.807 (0.204) 2.3 % -0.81 [ -1.21, -0.41 ]
Subtotal (95% CI) 1889 1054 36.8 % -0.31 [ -0.47, -0.15 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 37.08, df = 9 (P = 0.00003); I2 =76%
Test for overall effect: Z = 3.70 (P = 0.00021)
7 Oxymorphone
Kivitz 2006 270 87 -0.391 (0.124) 4.0 % -0.39 [ -0.63, -0.15 ]
Matsumoto 2005 228 60 -0.395 (0.147) 3.4 % -0.40 [ -0.68, -0.11 ]
Subtotal (95% CI) 498 147 7.4 % -0.39 [ -0.58, -0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.14 (P = 0.000034)
8 Tapentadol
Afilalo 2010 344 169 -0.296 (0.094) 4.8 % -0.30 [ -0.48, -0.11 ]
Etropolski 2011 304 74 -0.364 (0.13) 3.8 % -0.36 [ -0.62, -0.11 ]
Hartrick 2009 330 86 -0.51 (0.122) 4.0 % -0.51 [ -0.75, -0.27 ]
NCT00486811 319 169 -0.142 (0.095) 4.8 % -0.14 [ -0.33, 0.04 ]
Subtotal (95% CI) 1297 498 17.5 % -0.31 [ -0.46, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.97, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 4.09 (P = 0.000043)
Total (95% CI) 5180 3095 100.0 % -0.28 [ -0.35, -0.20 ]
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Study or subgroup Opioids Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.02; Chi2 = 62.17, df = 26 (P = 0.00009); I2 =58%
Test for overall effect: Z = 7.26 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.57, df = 7 (P = 0.12), I2 =40%
-2 -1 0 1 2
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Analysis 1.2. Comparison 1 Opioids versus placebo, Outcome 2 Function.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 2 Function
Study or subgroup Opioids Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Buprenorphine
Breivik 2010 94 96 -0.241 (0.146) 6.4 % -0.24 [ -0.53, 0.05 ]
Munera 2010 149 162 -0.219 (0.114) 8.8 % -0.22 [ -0.44, 0.00 ]
Subtotal (95% CI) 243 258 15.2 % -0.23 [ -0.40, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Codeine
Kjaersgaard-Andersen 1990 43 60 -0.288 (0.201) 3.9 % -0.29 [ -0.68, 0.11 ]
Peloso 2000 31 35 -0.621 (0.253) 2.6 % -0.62 [ -1.12, -0.13 ]
Subtotal (95% CI) 74 95 6.5 % -0.42 [ -0.74, -0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 2.58 (P = 0.010)
3 Fentanyl
Langford 2006 202 197 -0.283 (0.101) 10.1 % -0.28 [ -0.48, -0.09 ]
Subtotal (95% CI) 202 197 10.1 % -0.28 [ -0.48, -0.09 ]
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(. . . Continued)
Study or subgroup Opioids Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
4 Morphine
Caldwell 2002 222 73 -0.311 (0.136) 7.0 % -0.31 [ -0.58, -0.04 ]
Katz 2010 171 173 -0.127 (0.108) 9.4 % -0.13 [ -0.34, 0.08 ]
Subtotal (95% CI) 393 246 16.4 % -0.20 [ -0.38, -0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.12, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 2.22 (P = 0.026)
5 Oxycodone
Afilalo 2010 92 79 -0.292 (0.154) 5.9 % -0.29 [ -0.59, 0.01 ]
Markenson 2005 56 51 -0.798 (0.201) 3.9 % -0.80 [ -1.19, -0.40 ]
Matsumoto 2005 120 59 -0.141 (0.159) 5.6 % -0.14 [ -0.45, 0.17 ]
NCT00486811 114 109 -0.047 (0.134) 7.2 % -0.05 [ -0.31, 0.22 ]
Subtotal (95% CI) 382 298 22.6 % -0.30 [ -0.58, -0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.27, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 2.00 (P = 0.046)
6 Oxymorphone
Kivitz 2006 270 87 -0.395 (0.124) 7.9 % -0.40 [ -0.64, -0.15 ]
Matsumoto 2005 228 60 -0.358 (0.146) 6.4 % -0.36 [ -0.64, -0.07 ]
Subtotal (95% CI) 498 147 14.3 % -0.38 [ -0.56, -0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.02 (P = 0.000059)
7 Tapentadol
Afilalo 2010 149 79 -0.308 (0.14) 6.8 % -0.31 [ -0.58, -0.03 ]
NCT00486811 183 109 0 (0.121) 8.2 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 332 188 14.9 % -0.15 [ -0.45, 0.16 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 2124 1429 100.0 % -0.26 [ -0.35, -0.17 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 20.50, df = 14 (P = 0.12); I2 =32%
Test for overall effect: Z = 5.91 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.70, df = 6 (P = 0.72), I2 =0.0%
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Analysis 1.3. Comparison 1 Opioids versus placebo, Outcome 3 Number of participants experiencing any
adverse event.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 3 Number of participants experiencing any adverse event
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Buprenorphine
Breivik 2010 92/100 73/99 8.5 % 1.25 [ 1.09, 1.42 ]
Subtotal (95% CI) 100 99 8.5 % 1.25 [ 1.09, 1.42 ]
Total events: 92 (Opioids), 73 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00093)
2 Codeine
Peloso 2000 25/31 22/35 4.8 % 1.28 [ 0.94, 1.75 ]
Subtotal (95% CI) 31 35 4.8 % 1.28 [ 0.94, 1.75 ]
Total events: 25 (Opioids), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
3 Fentanyl
Langford 2006 169/216 101/200 8.0 % 1.55 [ 1.33, 1.81 ]
Subtotal (95% CI) 216 200 8.0 % 1.55 [ 1.33, 1.81 ]
Total events: 169 (Opioids), 101 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.57 (P < 0.00001)
4 Morphine
Katz 2010 91/171 84/173 6.8 % 1.10 [ 0.89, 1.35 ]
Subtotal (95% CI) 171 173 6.8 % 1.10 [ 0.89, 1.35 ]
Total events: 91 (Opioids), 84 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
5 Oxycodone
Afilalo 2010 299/342 103/169 8.6 % 1.43 [ 1.26, 1.63 ]
Etropolski 2011 114/143 31/74 5.3 % 1.90 [ 1.44, 2.52 ]
Hartrick 2009 144/172 27/85 4.6 % 2.64 [ 1.92, 3.62 ]
Markenson 2005 52/56 28/51 5.7 % 1.69 [ 1.31, 2.19 ]
Matsumoto 2005 110/125 35/62 6.3 % 1.56 [ 1.24, 1.96 ]
NCT00486811 294/331 95/169 8.4 % 1.58 [ 1.38, 1.81 ]
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Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1169 610 38.9 % 1.69 [ 1.47, 1.95 ]
Total events: 1013 (Opioids), 319 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 13.99, df = 5 (P = 0.02); I2 =64%
Test for overall effect: Z = 7.34 (P < 0.00001)
6 Oxymorphone
Matsumoto 2005 223/242 36/62 6.6 % 1.59 [ 1.28, 1.97 ]
Subtotal (95% CI) 242 62 6.6 % 1.59 [ 1.28, 1.97 ]
Total events: 223 (Opioids), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P = 0.000025)
7 Tapentadol
Afilalo 2010 261/344 103/169 8.4 % 1.24 [ 1.09, 1.42 ]
Etropolski 2011 199/305 31/74 5.3 % 1.56 [ 1.18, 2.06 ]
Hartrick 2009 201/325 27/85 4.6 % 1.95 [ 1.41, 2.69 ]
NCT00486811 216/319 95/169 8.0 % 1.20 [ 1.03, 1.40 ]
Subtotal (95% CI) 1293 497 26.3 % 1.39 [ 1.17, 1.66 ]
Total events: 877 (Opioids), 256 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.94, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 3.68 (P = 0.00023)
Total (95% CI) 3222 1676 100.0 % 1.49 [ 1.35, 1.63 ]
Total events: 2490 (Opioids), 891 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 47.91, df = 14 (P = 0.00001); I2 =71%
Test for overall effect: Z = 8.38 (P < 0.00001)
Test for subgroup differences: Chi2 = 18.44, df = 6 (P = 0.01), I2 =67%
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Analysis 1.4. Comparison 1 Opioids versus placebo, Outcome 4 Number of participants who withdrew
because of adverse events.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 4 Number of participants who withdrew because of adverse events
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Buprenorphine
Breivik 2010 31/100 2/99 2.3 % 15.35 [ 3.77, 62.39 ]
Munera 2010 36/152 18/163 5.9 % 2.14 [ 1.27, 3.61 ]
NCT00531427 44/282 30/285 6.4 % 1.48 [ 0.96, 2.29 ]
Shannon 2005 8/164 1/162 1.2 % 7.90 [ 1.00, 62.47 ]
Subtotal (95% CI) 698 709 15.8 % 3.10 [ 1.38, 6.94 ]
Total events: 119 (Opioids), 51 (Control)
Heterogeneity: Tau2 = 0.42; Chi2 = 11.70, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 2.75 (P = 0.0060)
2 Codeine
Kjaersgaard-Andersen 1990 40/83 10/75 5.3 % 3.61 [ 1.95, 6.71 ]
Peloso 2000 15/51 4/52 3.4 % 3.82 [ 1.36, 10.74 ]
Quiding 1992 0/8 0/8 Not estimable
Subtotal (95% CI) 142 135 8.7 % 3.67 [ 2.16, 6.24 ]
Total events: 55 (Opioids), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
3 Fentanyl
Langford 2006 54/202 20/197 6.2 % 2.63 [ 1.64, 4.23 ]
Subtotal (95% CI) 202 197 6.2 % 2.63 [ 1.64, 4.23 ]
Total events: 54 (Opioids), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000062)
4 Hydromorphone
NCT00980798 36/139 7/149 4.5 % 5.51 [ 2.54, 11.98 ]
Subtotal (95% CI) 139 149 4.5 % 5.51 [ 2.54, 11.98 ]
Total events: 36 (Opioids), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000016)
5 Morphine
Caldwell 2002 53/222 5/73 4.0 % 3.49 [ 1.45, 8.39 ]
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(. . . Continued)
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Katz 2010 18/171 13/173 5.0 % 1.40 [ 0.71, 2.77 ]
Subtotal (95% CI) 393 246 9.0 % 2.12 [ 0.87, 5.15 ]
Total events: 71 (Opioids), 18 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 2.58, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.65 (P = 0.099)
6 Oxycodone
Afilalo 2010 146/342 11/169 5.5 % 6.56 [ 3.66, 11.77 ]
Chindalore 2005 79/309 0/51 0.7 % 26.67 [ 1.68, 423.49 ]
Etropolski 2011 35/143 2/74 2.3 % 9.06 [ 2.24, 36.61 ]
Friedmann 2011 43/201 22/207 6.2 % 2.01 [ 1.25, 3.24 ]
Hartrick 2009 52/172 3/85 3.0 % 8.57 [ 2.75, 26.63 ]
Markenson 2005 20/56 2/51 2.3 % 9.11 [ 2.24, 37.05 ]
Matsumoto 2005 31/125 3/62 3.0 % 5.13 [ 1.63, 16.11 ]
NCT00486811 135/333 14/169 5.9 % 4.89 [ 2.91, 8.22 ]
Zautra 2005 20/55 2/49 2.3 % 8.91 [ 2.19, 36.19 ]
Subtotal (95% CI) 1736 917 31.1 % 5.55 [ 3.47, 8.87 ]
Total events: 561 (Opioids), 59 (Control)
Heterogeneity: Tau2 = 0.24; Chi2 = 18.39, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 7.15 (P < 0.00001)
7 Oxymorphone
Kivitz 2006 122/279 9/91 5.3 % 4.42 [ 2.34, 8.34 ]
Matsumoto 2005 103/242 3/62 3.1 % 8.80 [ 2.89, 26.79 ]
Subtotal (95% CI) 521 153 8.3 % 5.32 [ 2.93, 9.68 ]
Total events: 225 (Opioids), 12 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 5.48 (P < 0.00001)
8 Tapentadol
Afilalo 2010 66/344 11/169 5.4 % 2.95 [ 1.60, 5.43 ]
Etropolski 2011 27/305 2/74 2.2 % 3.28 [ 0.80, 13.47 ]
Hartrick 2009 52/325 3/85 3.0 % 4.53 [ 1.45, 14.16 ]
NCT00486811 60/320 14/169 5.7 % 2.26 [ 1.30, 3.93 ]
Subtotal (95% CI) 1294 497 16.3 % 2.76 [ 1.90, 4.00 ]
Total events: 205 (Opioids), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.35 (P < 0.00001)
Total (95% CI) 5125 3003 100.0 % 3.76 [ 2.93, 4.82 ]
Total events: 1326 (Opioids), 211 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 58.60, df = 24 (P = 0.00010); I2 =59%
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(. . . Continued)
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 10.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.20, df = 7 (P = 0.13), I2 =37%
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Analysis 1.5. Comparison 1 Opioids versus placebo, Outcome 5 Number of participants experiencing any
serious adverse event.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 5 Number of participants experiencing any serious adverse event
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Kjaersgaard-Andersen 1990 0/83 0/75 Not estimable
Subtotal (95% CI) 83 75 Not estimable
Total events: 0 (Opioids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Fentanyl
Langford 2006 6/216 2/200 77.4 % 2.78 [ 0.57, 13.60 ]
Subtotal (95% CI) 216 200 77.4 % 2.78 [ 0.57, 13.60 ]
Total events: 6 (Opioids), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Oxycodone
Markenson 2005 3/56 0/51 22.6 % 6.39 [ 0.34, 120.71 ]
Subtotal (95% CI) 56 51 22.6 % 6.39 [ 0.34, 120.71 ]
Total events: 3 (Opioids), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Total (95% CI) 355 326 100.0 % 3.35 [ 0.83, 13.56 ]
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(. . . Continued)
Study or subgroup Opioids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 9 (Opioids), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.63), I2 =0.0%
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Analysis 1.6. Comparison 1 Opioids versus placebo, Outcome 6 Withdrawal symptoms.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 6 Withdrawal symptoms
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Oxycodone
Afilalo 2010 0.778 (0.652) 5.9 % 2.18 [ 0.61, 7.81 ]
Subtotal (95% CI) 5.9 % 2.18 [ 0.61, 7.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 Morphine
Katz 2010 1.116 (1.637) 0.9 % 3.05 [ 0.12, 75.52 ]
Subtotal (95% CI) 0.9 % 3.05 [ 0.12, 75.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Tapentadol
Afilalo 2010 -0.01 (0.709) 5.0 % 0.99 [ 0.25, 3.97 ]
Subtotal (95% CI) 5.0 % 0.99 [ 0.25, 3.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Fentanyl
Langford 2006 1.089 (0.169) 88.1 % 2.97 [ 2.13, 4.14 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 88.1 % 2.97 [ 2.13, 4.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.44 (P < 0.00001)
Total (95% CI) 100.0 % 2.76 [ 2.02, 3.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.42, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.42, df = 3 (P = 0.49), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Stratified analyses: pain
Variable Number of
studies
N of partici-
pants
opioids
N of partici-
pants
control
Pain intensity
SMD (95% CI)
Heterogeneity
I2 (%)
P value*
All trials 22 5180 3095 -0.28 (-0.35 to -
0.20)
58%
Analgesic potency 0.32
Weak 3 79 100 -0.51 (-1.01 to -
0.01)
55%
Strong 19 5101 2995 -0.26 (-0.35 to -
0.18)
64%
Route of administration 0.36
Oral 17 4287 2188 -0.30 (-0.41 to -
0.20)
70%
Transdermal 5 893 907 -0.20 (-0.29 to -
0.11)
0%
Allocation concealment 0.31
Adequate 8 1981 1141 -0.32 (-0.44 to -
0.21)
48%
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Table 1. Stratified analyses: pain (Continued)
Inadequate or
unclear
14 3199 1954 -0.24 (-0.35 to -
0.13)
67%
Blinding of participants 0.23
Adequate 15 3050 1616 -0.32 (-0.42 to -
0.22)
53%
Inadequate or
unclear
7 2130 1479 -0.21 (-0.34 to -
0.08)
73%
Intention-to-treat analysis 0.43
Yes 1 283 287 -0.14 (-0.30 to 0.
02)
N/A
No or unclear 21 4897 2808 -0.29 (-0.37 to -
0.20)
63%
Type of control intervention 0.97
Placebo 20 5132 3030 -0.28 (-0.36 to -
0.19)
65%
No intervention 2 48 65 -0.33 (-0.93 to 0.
28)
35%
Number of participants randomised 0.08
> 200 16 4895 2796 -0.24 (-0.33 to -
0.16)
64%
≤ 200 6 285 299 -0.47 (-0.71 to -
0.23)
48%
Duration of treatment 0.001
> 1 month 10 2635 1972 -0.15 (-0.22 to -
0.08)
25%
≤ 1 month 12 2545 1123 -0.40 (-0.50 to -
0.30)
37%
Use of analgesic co-interventions 0.59
Similar between
groups
6 1189 891 -0.31 (-0.46 to -
0.16)
60%
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Table 1. Stratified analyses: pain (Continued)
Unclear 16 3991 2204 -0.26 (-0.36 to -
0.16)
65%
Type of osteoarthritis 0.77
Hip only 2 48 65 -0.33 (-0.93 to 0.
28)
35%
Knee only 4 1674 1010 -0.22 (-0.41 to -
0.04)
78%
Knee and hip 16 3458 2020 -0.29 (-0.38 to -
0.20)
56%
*P value for interaction. N/A: not available.
Table 2. Stratified analyses: function
Variable Number of
studies
N of partici-
pants
opioids
N of partici-
pants
control
Function
SMD (95% CI)
Heterogeneity
I2 (%)
P value*
All trials 12 2124 1429 -0.26 (-0.35 to -
0.17)
32%
Analgesic potency 0.42
Weak 2 74 95 -0.42 (-0.74 to -
0.10)
6%
Strong 10 2050 1334 -0.26 (-0.36 to -
0.16)
48%
Route of administration 0.76
Oral 9 1679 974 -0.30 (-0.43 to -
0.16)
58%
Transdermal 3 445 455 -0.25 (-0.38 to -
0.12)
0%
Allocation concealment 0.43
Adequate 6 1034 762 -0.32 (-0.45 to -
0.18)
47%
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Table 2. Stratified analyses: function (Continued)
Inadequate or
unclear
6 1090 667 -0.23 (-0.37 to -
0.09)
39%
Blinding of participants 0.008
Adequate 10 1656 1038 -0.32 (-0.40 to -
0.24)
0%
Inadequate or
unclear
2 468 391 -0.07 (-0.20 to 0.
07)
0%
Intention-to-treat analysis 0.34
Yes 1 171 173 -0.13 (-0.34 to 0.
08)
N/A
No or unclear 11 1953 1256 -0.29 (-0.40 to -
0.19)
44%
Type of control intervention 0.96
Placebo 11 2081 1369 -0.28 (-0.38 to -
0.18)
49%
No intervention 1 43 60 -0.29 (-0.68 to 0.
11)
N/A
Number of participants randomised 0.11
> 200 8 1900 1187 -0.23 (-0.32 to -
0.14)
26%
≤ 200 4 224 242 -0.46 (-0.73 to -
0.19)
51%
Duration of treatment 0.41
> 1 month 6 1061 893 -0.25 (-0.41 to -
0.09)
66%
≤ 1 month 6 1063 536 -0.31 (-0.42 to -
0.20)
0%
Use of analgesic co-interventions 0.38
Similar between
groups
4 460 456 -0.40 (-0.67 to -
0.13)
71%
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Table 2. Stratified analyses: function (Continued)
Unclear 8 1664 973 -0.24 (-0.33 to -
0.15)
16%
Type of osteoarthritis 0.45
Hip only 1 43 60 -0.29 (-0.68 to 0.
11)
N/A
Knee only 2 538 376 -0.16 (-0.43 to 0.
11)
76%
Knee and hip 9 1543 993 -0.31 (-0.41 to -
0.20)
31%
*P value for interaction. N/A: not available.
A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE, and CINAHL search strategy
Ovid MEDLINE Ovid EMBASE CINAHL through EBSCOhost
Search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
11. placebos.sh.
12. placebo$.ti,ab.
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
Search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
11. methodology.sh.
12. comparative study.sh.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or volunteer$)
.ti,ab.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”) or (MH
“Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
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18. prospective studies.sh.
19. (control$ or prospectiv$ or volunteer$)
.ti,ab.
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or volun-
teer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. exp osteoarthritis/
21. osteoarthriti$.ti,ab,sh.
22. osteoarthro$.ti,ab,sh.
23. gonarthriti$.ti,ab,sh.
24. gonarthro$.ti,ab,sh.
25. coxarthriti$.ti,ab,sh.
26. coxarthro$.ti,ab,sh.
27. arthros$.ti,ab.
28. arthrot$.ti,ab.
29. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
30. ((knee$ or hip$ or joint$) adj3 stiff$).
ti,ab.
Search terms for Osteoarthritis
17. exp osteoarthritis/
18. osteoarthriti$.ti,ab,sh.
19. osteoarthro$.ti,ab,sh.
20. gonarthriti$.ti,ab,sh.
21. gonarthro$.ti,ab,sh.
22. coxarthriti$.ti,ab,sh.
23. coxarthro$.ti,ab,sh.
24. arthros$.ti,ab.
25. arthrot$.ti,ab.
26. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
27. ((knee$ or hip$ or joint$) adj3 stiff$).
ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
36. TX joint$ n3 ach$
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for Opioids
31. exp Analgesics, Opioid/
32. exp Narcotics/
33. acetyldihydrocodeine.tw.
34. alfentanil.tw.
35. allylprodine.tw.
36. alphamethylfentanyl.tw.
37. alphaprodine.tw.
38. benzylmorphine.tw.
39. betaprodine.tw.
40. bezitriamide.tw.
41. buprenorphine.tw.
42. butorphanol.tw.
43. bremazocine.tw.
44. carfentan$.tw.
45. codeine.tw.
46. contin.tw.
47. dextromoramide.tw.
48. dextropropoxyphene.tw.
Search terms for Opioids
28. exp Analgesics, Opioid/
29. exp Narcotic Analgesic Agent/
30. acetyldihydrocodeine.tw.
31. alfentanil.tw.
32. allylprodine.tw.
33. alphamethylfentanyl.tw.
34. alphaprodine.tw.
35. benzylmorphine.tw.
36. betaprodine.tw.
37. bezitriamide.tw.
38. buprenorphine.tw.
39. butorphanol.tw.
40. bremazocine.tw.
41. carfentan$.tw.
42. codeine.tw.
43. contin.tw.
44. dextromoramide.tw.
45. dextropropoxyphene.tw.
Search terms for Opioids
44. MH “ Analgesics, Opioid”
45. MH “Narcotics”
46. TX acetyldihydrocodeine
47. TX alfentanil
48. TX allylprodine
49. TX alphamethylfentanyl
50. TX alphaprodine
51. TX benzylmorphine
52. TX betaprodine
53. TX bezitriamide
54. TX buprenorphine
55. TX butorphanol
56. TX bremazocine
57. TX carfentan$
58. TX codeine
58. TX contin
60. TX dextromoramide
61. TX dextropropoxyphene
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49. dezocine.tw.
50. diacetylmorphine.tw.
51. diamorphine.tw.
52. dihydrocodeine.tw.
53. dihydromorphine.tw.
54. dihydromorphone.tw.
55. diphenoxylate.tw.
56. dipipanone.tw.
57. enadoline.tw.
58. ethylketazocine.tw.
59. ethylmorphine.tw.
60. etonitazene.tw.
61. etorphine.tw.
62. fentanyl.tw.
63. heroin.tw.
64. hydrocodone.tw.
65. hydromorphin$.tw.
66. hydromorphone.tw.
67. ketazocine.tw.
68. ketobemidone.tw.
69. lefetamine.tw.
70. levomethadon.tw.
71. levomethadyl.tw.
72. levomethorphan$.tw.
73. levorphanol.tw.
74. loperamide.tw.
75. meperidine.tw.
76. meptazinol.tw.
77. methadone.tw.
78. methadyl.tw.
79. methylmorphine.tw.
80. morphin$.tw.
81. nalbuphine.tw.
82. narcotic$.tw.
83. nicocodeine.tw.
84. nicomorphine.tw.
85. normorphine.tw.
86. noscapin$.tw.
87. ohmefentanyl.tw.
88. opiate$.tw.
89. opioid$.tw.
90. opium.tw.
91. oripavine.tw.
92. oxycodone.tw.
93. oxycontin.tw.
94. oxymorphone.tw.
95. papaveretum.tw.
96. papaverin.tw.
97. pentazocine.tw.
46. dezocine.tw.
47. diacetylmorphine.tw.
48. diamorphine.tw.
49. dihydrocodeine.tw.
50. dihydromorphine.tw.
51. dihydromorphone.tw.
52. diphenoxylate.tw.
53. dipipanone.tw.
54. enadoline.tw.
55. ethylketazocine.tw.
56. ethylmorphine.tw.
57. etonitazene.tw.
58. etorphine.tw.
59. fentanyl.tw.
60. heroin.tw.
61. hydrocodone.tw.
62. hydromorphin$.tw.
63. hydromorphone.tw.
64. ketazocine.tw.
65. ketobemidone.tw.
66. lefetamine.tw.
67. levomethadon.tw.
68. levomethadyl.tw.
69. levomethorphan$.tw.
70. levorphanol.tw.
71. loperamide.tw.
72. meperidine.tw.
73. meptazinol.tw.
74. methadone.tw.
75. methadyl.tw.
76. methylmorphine.tw.
77. morphin$.tw.
78. nalbuphine.tw.
79. narcotic$.tw.
80. nicocodeine.tw.
81. nicomorphine.tw.
82. normorphine.tw.
83. noscapin$.tw.
84. ohmefentanyl.tw.
85. opiate$.tw.
86. opioid$.tw.
87. opium.tw.
88. oripavine.tw.
89. oxycodone.tw.
90. oxycontin.tw.
91. oxymorphone.tw.
92. papaveretum.tw.
93. papaverin.tw.
62. TX dezocine
63. TX diacetylmorphine
64. TX diamorphine
65. TX dihydrocodeine
66. TX dihydromorphine
67. TX dihydromorphone
68. TX diphenoxylate
69. TX dipipanone
70. TX enadoline
71. TX ethylketazocine
72. TX ethylmorphine
73. TX etonitazene
74. TX etorphine
75. TX fentanyl
76. TX heroin
77. TX hydrocodone
78. TX hydromorphin$
79. TX hydromorphone
80. TX ketazocine
81. TX ketobemidone
82. TX lefetamine
83. TX levomethadon
84. TX levomethadyl
85. TX levomethorphan$
86. TX levorphanol
87. TX loperamide
88. TX meperidine
89. TX meptazinol
90. TX methadone
91. TX methadyl
92. TX methylmorphine
93. TX morphin$
94. TX nalbuphine
95. TX narcotic$
96. TX nicocodeine
97. TX nicomorphine
98. TX normorphine
99. TX noscapin$
100. TX ohmefentanyl
101. TX opiate$
102. TX opioid$
103. TX opium
104. TX oripavine
105. TX oxycodone
106. TX oxycontin
107. TX oxymorphone
108. TX papaveretum
109. TX papaverin
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98. percocet.tw.
99. peronine.tw.
100. pethidine.tw.
101. phenazocine.tw.
102. phencyclidine.tw.
103. pholcodine.tw.
104. piritramid$.tw.
105. prodine.tw.
106. promedol.tw.
107. propoxyphene.tw.
108. remifentanil.tw.
109. sufentanil.tw.
110. tapentadol.tw.
111. thebaine.tw.
112. tilidine.tw.
94. pentazocine.tw.
95. percocet.tw.
96. peronine.tw.
97. pethidine.tw.
98. phenazocine.tw.
99. phencyclidine.tw.
100. pholcodine.tw.
101. piritramid$.tw.
102. prodine.tw.
103. promedol.tw.
104. propoxyphene.tw.
105. remifentanil.tw.
106. sufentanil.tw.
107. tapentadol.tw.
108. thebaine.tw.
109. tilidine.tw.
110. TX pentazocine
111. TX percocet
112. TX peronine
113. TX pethidine
114. TX phenazocine
115. TX phencyclidine
116. TX pholcodine
117. TX piritramid$
118. TX prodine
119. TX promedol
120. TX propoxyphene
121. TX remifentanil
122. TX sufentanil
123. TX tapentadol
124. TX thebaine
125. TX tilidine
126. S44 or S45 or S125
Combining terms
113. or/31-112
114. or/1-19
115. or/20-30
116. and/113-115
117. animal/
118. animal/ and human/
119. 117 not 118
120. 116 not 119
121. remove duplicates from 120
Combining terms
110. or/28-109
111. or/1-16
112. or/17-27
113. and/110-112
114. animal/
115. animal/ and human/
116. 114 not 115
117. 113 not 116
118. remove duplicates from 117
Combining terms
127. S21 and S43 and S126
Appendix 2. CENTRAL search strategy
CENTRAL
Search terms for Osteoarthritis
#1. MeSH descriptor Osteoarthritis explode all trees
#2. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
Search terms for Opioids
#3. MeSH descriptor Analgesics, Opioid explode all trees
#4. MeSH descriptor Narcotics explode all trees
#5. (acetyldihydrocodeine OR alfentanil OR allylprodine OR
alphamethylfentanyl OR alphaprodine OR benzylmorphine OR
betaprodine OR bezitriamide OR buprenorphine OR butorphanol
OR bremazocine OR carfentan* OR codeine OR contin OR
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dextromoramide OR dextropropoxyphene OR dezocine OR
diacetylmorphine OR diamorphine OR dihydrocodeine OR
dihydromorphine OR dihydromorphone OR diphenoxylate OR
dipipanone OR enadoline OR ethylketazocine OR ethylmorphine OR
etonitazene OR etorphine OR fentanyl OR heroin OR hydrocodone
OR hydromorphin* OR hydromorphone OR ketazocine OR
ketobemidone OR lefetamine OR levomethadon OR levomethadyl
OR levomethorphan* OR levorphanol OR loperamide OR
meperidine OR meptazinol OR methadone OR methadyl OR
methylmorphine OR morphin* OR nalbuphine OR narcotic* OR
nicocodeine OR nicomorphine OR normorphine OR noscapin* OR
ohmefentanyl OR opiate* OR opioid* OR opium OR oripavine OR
oxycodone OR oxycontin OR oxymorphone OR papaveretum OR
papaverin OR pentazocine OR percocet OR peronine OR pethidine
OR phenazocine OR phencyclidine OR pholcodine OR piritramid*
OR prodine OR promedol OR propoxyphene OR remifentanil OR
sufentanil OR tapentadol OR thebaine OR tilidine) in Clinical Trials
Combining terms
#6. (#1 OR #2)
#7. (#3 OR #4 OR #5)
#8. (#6 AND #7) in Clinical Trials
WH A T ’ S N E W
Last assessed as up-to-date: 15 August 2012.
Date Event Description
22 March 2013 New search has been performed Search updated with 12 additional trials included.
22 August 2012 New citation required but conclusions have not changed Change in authorship
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H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 4, 2009
Date Event Description
8 October 2009 Amended NNTs for pain and function were corrected
13 May 2008 Amended Change in authorship
1 May 2008 Amended CMSG ID C141-R
C O N T R I B U T I O N S O F A U T H O R S
Protocol completion: Nüesch, Rutjes, Husni, Jüni.
Acquisition of data: Nüesch, da Costa, Kasteler, Rutjes.
Analysis and interpretation of data: Nüesch, da Costa, Kasteler, Husni, Welch, Rutjes, Jüni.
Manuscript preparation: Nüesch, da Costa, Kasteler, Husni, Welch, Rutjes, Jüni.
Statistical analysis: Nüesch, da Costa, Rutjes, Jüni.
Drs. Nüesch and da Costa contributed equally to this review.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• Institute of Social and Preventive Medicine, University or Bern, Switzerland.
Intramural grants
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External sources
• Swiss National Science Foundation, Switzerland.
National Research Program 53 on musculoskeletal health (grant numbers 4053-40-104762/3 and 3200-066378)
• Marie Curie Intra-European Fellowship, Other.
Dr Nüesch was recipient of a Marie Curie Intra-European Fellowship for Career Development (grant number FP7-PEOPLE-2010-
IEF-273673)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The cut-off to distinguish between short-term and long-term trials was changed from26weeks to onemonth. Sixmonthswas considered
to be rather long as the cut-off for an agent that is not considered to be a structure-modifying drug. In the absence of definitions for
short-term treatment in osteoarthritis treatment guidelines, we used the median follow-up duration in the trials included in the first
review (four weeks) as a cut-off to discriminate between trials of shorter and longer duration.
We did not include the electronic database CINAHL in our search update since, in our previous search, this database did not identify
any additional hits. Finally, we did not include the OARSI database in our search update, as we no longer had access to this database.
We added analyses stratified by type of osteoarthritis (hip only versus knee only versus mixed) upon request of peer reviewers.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Cutaneous; Administration, Oral; Analgesics, Opioid [∗administration & dosage; adverse effects]; Osteoarthritis, Hip
[∗drug therapy]; Osteoarthritis, Knee [∗drug therapy]; Pain Measurement; Randomized Controlled Trials as Topic
MeSH check words
Humans
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